var title_f33_1_33808="Operative approach for a preperitoneal inguinal hernia repair";
var content_f33_1_33808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Operative approach for a preperitoneal inguinal hernia repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the cross-sectional anatomy of the right lower abdominal wall showing the preperitoneal space. This appraoch can be used for repair of a primary inguinal hernia or recurrent inguinal hernia previously repaired by an anterior mesh repair or a failed posterior approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33808=[""].join("\n");
var outline_f33_1_33808=null;
var title_f33_1_33809="Elbow fusion";
var content_f33_1_33809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusion of elbow ossification centers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The secondary ossification centers fuse to create the mature bony elbow. The lateral epicondyle, trochlear, and capitellar centers fuse first; this unit then fuses with the distal humerus; the last fusion occurs at the medial epicondyle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from DeLee, JC, Drez, D (Eds). Orthopaedic sports medicine: Principles and practice, W.B. Saunders, Philadelphia 1994. Copyright &copy; 1994 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33809=[""].join("\n");
var outline_f33_1_33809=null;
var title_f33_1_33810="Elliptical method for calculating abdominal circumference";
var content_f33_1_33810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Elliptical method for calculating abdominal circumference",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AC: abdominal circumference",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jennifer T Ahn, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33810=[""].join("\n");
var outline_f33_1_33810=null;
var title_f33_1_33811="Tetralogy Fallot PA angio I";
var content_f33_1_33811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64416%7ECARD%2F78255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64416%7ECARD%2F78255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Main pulmonary artery angiogram in tetralogy of Fallot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An angled angiogram performed in the main pulmonary artery demonstrates severe proximal left pulmonary artery (LPA) stenosis (*). There is discrepancy in size between the proximal right pulmonary artery (RPA) and the proximal LPA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Main pulmonary artery angiogram after stenting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following placement of a balloon expandable stent in the proximal left pulmonary artery (*) of a patient with tetralogy of Fallot there is significant improvement in size of the proximal left pulmonary artery (LPA).",
"    <div class=\"footnotes\">",
"     RPA: right pulmonary artery; RV: right ventricle; MPA: main pulmonary artery.",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33811=[""].join("\n");
var outline_f33_1_33811=null;
var title_f33_1_33812="Liposomal vincristine: Patient drug information";
var content_f33_1_33812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Liposomal vincristine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/2/8231?source=see_link\">",
"     see \"Liposomal vincristine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14960115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14960117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14960116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vincristine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3887086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Charcot-Marie-Tooth syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14960120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14960121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14960122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain in the upper, right side.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14960119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14960123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86368 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-217.117.136.88-1821A5D3A7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33812=[""].join("\n");
var outline_f33_1_33812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960115\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960117\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960116\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960120\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960121\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960122\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960119\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960123\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/2/8231?source=related_link\">",
"      Liposomal vincristine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_1_33813="Amyl nitrite: Drug information";
var content_f33_1_33813=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amyl nitrite: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/55/42867?source=see_link\">",
"    see \"Amyl nitrite: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/25/405?source=see_link\">",
"    see \"Amyl nitrite: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F135363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F135350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Inhalation: 2-6 nasal inhalations from 1 crushed ampul; may repeat in 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cyanide poisoning (unlabeled use):",
"     </b>",
"     Inhalation: 0.3 mL ampul crushed into a gauze pad and placed in front of the patient&rsquo;s mouth (or endotracheal tube if patient is intubated) to inhale over 15-30 seconds; repeat every minute until sodium nitrite can be administered.",
"     <b>",
"      Note:",
"     </b>",
"     Must separate administrations by at least 30 seconds to allow for adequate oxygenation; each ampul will last for ~3 minutes  Amyl nitrite is a temporary intervention that should only be used until I.V. sodium nitrite infusion is ready for administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharmacologic provocation of latent left ventricular outflow tract (LVOT) gradient in hypertrophic cardiomyopathy (HCM) (unlabeled use):",
"     </b>",
"     Nasal inhalation: 3-4 deep inhalations from 1 crushed ampul over a 10-15 second period (Gersh, 2011; Nagueh, 2011; Reagan, 2005).",
"     <b>",
"      Note:",
"     </b>",
"     The use of more physiologic testing (eg, treadmill testing with Doppler echocardiography) may be preferred over amyl nitrite inhalation (Maron, 2003: Nagueh, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13386289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/25/405?source=see_link\">",
"      see \"Amyl nitrite: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cyanide poisoning (unlabeled use):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F135351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, for inhalation: USP: 85% to 103% (0.3 mL) [crushable covered glass capsule]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F135337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer nasally via inhalation. The patient should be lying down during administration. Crush the ampul in a gauze pad and place in front of patient&rsquo;s mouth (or endotracheal tube if intubated) and allow patient to inhale for 15-30 seconds; repeat every minute until sodium nitrite can be administered. One ampul lasts for ~3 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F135336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coronary vasodilator in angina pectoris",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Given the widespread use of newer nitrate compounds, the use of amyl nitrite for patients experiencing angina pectoris has fallen out of favor.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13386018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct treatment of cyanide toxicity; produce changes in the intensity of heart murmurs; provocation of latent left ventricular outflow tract (LVOT) gradient during echocardiography in patients with hypertrophic cardiomyopathy (HCM)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cerebral ischemia, facial flushing, hypotension, orthostatic hypotension, pallor, shock, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, intracranial pressure increased, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Fecal incontinence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemolytic anemia, methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F135340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glaucoma; recent head trauma or cerebral hemorrhage; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F135324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Amyl nitrite may cause severe hypotension resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation; ensure patient is euvolemic. Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with pre-existing diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise) and in patients who may be susceptible to injury from vasodilation; the use of hydroxocobalamin is recommended in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia: Amyl nitrite may cause methemoglobin formation resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation.  Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with pre-existing diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise), and in patients at greater risk for developing methemoglobinemia (eg, congenital methemoglobin reductase deficiency); the use of hydroxocobalamin is recommended in these patients. Use with caution with concomitant medications known to cause methemoglobinemia (eg, nitroglycerin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with extreme caution or avoid in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia; considered by some to be a contraindication (Reagan, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery disease and patients with hypotension. Transient episodes of dizziness, weakness, syncope, and cerebral ischemia secondary to postural hypotension may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure: Use with caution in patients with increased intracranial pressure; use is contraindicated in patient with recent head trauma or cerebral hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In these patients, the induction of methemoglobinemia (due to amyl nitrite) is contraindicated until carbon monoxide levels return to normal due to the risk of tissue hypoxia. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. Hydroxocobalamin, however, may be considered because sodium thiosulfate has a slow onset of action.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Methemoglobin reductase, which is responsible for converting methemoglobin back to hemoglobin, has reduced activity in pediatric patients. In addition, infants and young children have some proportion of fetal hemoglobin which forms methemoglobin more readily than adult hemoglobin. Therefore, pediatric patients (eg, neonates and infants &lt;6 months) are more susceptible to excessive nitrite-induced methemoglobinemia. Hydroxocobalamin may be a more effective and rapid alternative.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Nitrites should be avoided due to fetal hemoglobin's susceptibility to oxidative stress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Cyanide poisoning: Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain. However, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed.  Treatment of cyanide poisoning should include decontamination and supportive therapy. Consider consultation with a poison control center at 1-800-222-1222.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Initiation of treatment: Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Return of symptoms: Patients receiving treatment for acute cyanide toxicity must be monitored for return of symptoms for 24-48 hours; repeat therapy should be administered if symptoms return.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smoke inhalation: Use nitrites cautiously in patients with cyanide poisoning related to smoke inhalation because methemoglobinemia and carboxyhemoglobinemia may worsen oxygen-carrying capacity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F135329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Amyl Nitrite.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13315273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Because amyl nitrate significantly decreases systemic blood pressure and therefore blood flow to the fetus, use is contraindicated in pregnancy (per manufacturer). In addition, fetal hemoglobin may be more susceptible methemoglobin conversion (Valenzuela, 1986).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F135354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Amyl Nitrite Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mL (1): $0.63",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F135333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure and heart rate during therapy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cyanide poisoning: Monitor for at least 24-48 hours after administration; blood pressure and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO",
"     <sub>",
"      2",
"     </sub>",
"     gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amyl Nitrite (NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2508782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial O",
"     <sub>",
"      2",
"     </sub>",
"     consumption. When used for cyanide poisoning, amyl nitrite promotes the formation of methemoglobin which competes with cytochrome oxidase for the cyanide ion. Cyanide combines with methemoglobin to form cyanomethemoglobin, thereby freeing the cytochrome oxidase and allowing aerobic metabolism to continue.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F135339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Angina: Within 30 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Angina: 3-15 minutes; Pharmacologic provocation of latent left ventricular outflow tract (LVOT) gradient in hypertrophic cardiomyopathy (HCM): ~30 seconds (Reagan, 2005)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Medical Management Guidelines for Hydrogen Cyanide (HCN).&rdquo; Available at",
"      <a href=\"file://www.atsdr.cdc.gov/MHMI/mmg8.pdf\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/MHMI/mmg8.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berlin CM, &ldquo;The Treatment of Cyanide Poisoning in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1970, 46(5):793-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/4320419/pubmed\" id=\"4320419\" target=\"_blank\">",
"        4320419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al, &ldquo;2008 Focused Update Incorporated into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 118(15):e523-661.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/18820172/pubmed\" id=\"18820172\" target=\"_blank\">",
"        18820172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller RJ, Barthold C, Saiers JA, et al, &ldquo;Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(5):2146-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/17079589/pubmed\" id=\"17079589\" target=\"_blank\">",
"        17079589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia R and Shepherd G, &ldquo;Cyanide Poisoning and Its Treatment,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(10):1358-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/15628833/pubmed\" id=\"15628833\" target=\"_blank\">",
"        15628833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin For The Empiric Treatment of Cyanide Poisoning?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2007, 49(6):806-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/19650716/pubmed\" id=\"19650716\" target=\"_blank\">",
"        19650716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011, 1519-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lavon O and Bentur Y, \"Does Amyl Nitrite Have a Role in the Management of Pre-Hospital Mass Casualty Cyanide Poisoning?\"",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2010, 48(6):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/20653465/pubmed\" id=\"20653465\" target=\"_blank\">",
"        20653465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marron BJ, McKenna WJ, Danielson GK, et al, &ldquo;American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 42(9):1687-713.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/14607462/pubmed\" id=\"14607462\" target=\"_blank\">",
"        14607462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagueh SF, Bierig SM, Budoff MJ, et al, &ldquo;American Society of Echocardiography Clinical Recommendations for Multimodality Cardiovascular Imaging of Patients With hypertrophic Cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography,&rdquo;",
"      <i>",
"       J Am Soc Echocardiogr",
"      </i>",
"      , 2011, 24(5):473-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/21514501/pubmed\" id=\"21514501\" target=\"_blank\">",
"        21514501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nichol LM, Mills NL, and Starkey IR, \"Amyl Nitrite Induced Cerebral and Coronary Vasospasm,\"",
"      <i>",
"       QJM",
"      </i>",
"      , 2011, 104(1):83-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/20843773/pubmed\" id=\"20843773\" target=\"_blank\">",
"        20843773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Valenzuela A, Guerra R, Lazcano L, et al, &ldquo;Differential Prooxidative Effect of Adult and Fetal Hemoglobin,\"",
"      <i>",
"       FEBS Lett",
"      </i>",
"      , 1986, 196(2):353-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/2419158/pubmed\" id=\"2419158\" target=\"_blank\">",
"        2419158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wesley Reagan B, Helmcke F, and Kenneth Kerut E, &ldquo;Commonly Used Respiratory and Pharmacologic Interventions in the Echocardiography Laboratory,&rdquo;",
"      <i>",
"       Echocardiography",
"      </i>",
"      , 2005, 22(5):455-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33813/abstract-text/15901303/pubmed\" id=\"15901303\" target=\"_blank\">",
"        15901303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8767 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33813=[""].join("\n");
var outline_f33_1_33813=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135363\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135350\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386289\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135351\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135335\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135321\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135337\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135336\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386018\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135361\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135340\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135324\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298751\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135329\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135331\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315273\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135354\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322991\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135333\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038529\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2508782\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135339\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8767\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8767|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/55/42867?source=related_link\">",
"      Amyl nitrite: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/25/405?source=related_link\">",
"      Amyl nitrite: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_1_33814="Seborrheic dermatitis scalp PI";
var content_f33_1_33814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dandruff is a mild form of seborrheic dermatitis. It causes white scales or flakes on the head or hair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33814=[""].join("\n");
var outline_f33_1_33814=null;
var title_f33_1_33815="Ranitidine: Pediatric drug information";
var content_f33_1_33815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ranitidine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"    see \"Ranitidine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/56/22405?source=see_link\">",
"    see \"Ranitidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zantac 150&reg; [OTC];",
"     </li>",
"     <li>",
"      Zantac 75&reg; [OTC];",
"     </li>",
"     <li>",
"      Zantac&reg;;",
"     </li>",
"     <li>",
"      Zantac&reg; EFFERdose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acid Reducer;",
"     </li>",
"     <li>",
"      Apo-Ranitidine&reg;;",
"     </li>",
"     <li>",
"      CO Ranitidine;",
"     </li>",
"     <li>",
"      Dom-Ranitidine;",
"     </li>",
"     <li>",
"      Myl-Ranitidine;",
"     </li>",
"     <li>",
"      Mylan-Ranitidine;",
"     </li>",
"     <li>",
"      Nu-Ranit;",
"     </li>",
"     <li>",
"      PHL-Ranitidine;",
"     </li>",
"     <li>",
"      PMS-Ranitidine;",
"     </li>",
"     <li>",
"      Ranitidine Injection, USP;",
"     </li>",
"     <li>",
"      RAN&trade;-Ranitidine;",
"     </li>",
"     <li>",
"      ratio-Ranitidine;",
"     </li>",
"     <li>",
"      Riva-Ranitidine;",
"     </li>",
"     <li>",
"      Sandoz-Ranitidine;",
"     </li>",
"     <li>",
"      ScheinPharm Ranitidine;",
"     </li>",
"     <li>",
"      Teva-Ranitidine;",
"     </li>",
"     <li>",
"      Zantac 75&reg;;",
"     </li>",
"     <li>",
"      Zantac Maximum Strength Non-Prescription;",
"     </li>",
"     <li>",
"      Zantac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Histamine H",
"       <sub>",
"        2",
"       </sub>",
"       Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 2 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: 1.5 mg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: 12 hours after loading dose, give 1.5-2 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous infusion: Loading dose: 1.5 mg/kg/dose, followed by 0.04-0.08 mg/kg/hour infusion (or 1-2 mg/kg/day)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"      see \"Ranitidine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents 1 month to 16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastric/duodenal ulcer:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Treatment: 4-8 mg/kg/day divided twice daily; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance: 2-4 mg/kg/day once daily; maximum: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 2-4 mg/kg/day divided every 6-8 hours; maximum: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GERD and erosive esophagitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 4-10 mg/kg/day divided twice daily; maximum: GERD: 300 mg/day; erosive esophagitis: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 2-4 mg/kg/day divided every 6-8 hours; maximum: 200 mg/day",
"     <b>",
"      or as an alternative",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion: Initial: 1 mg/kg/dose for one dose followed by infusion of 0.08-0.17 mg/kg/hour or 2-4 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of duodenal or gastric ulcers, GERD, maintenance of erosive esophagitis: Oral: 150 mg/dose twice daily or 300 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis of recurrent duodenal ulcer: Oral: 150 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastric hypersecretory conditions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 150 mg twice daily; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 50 mg/dose every 6-8 hours (dose not to exceed 400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion: Initial 50 mg I.V. followed by 6.25 mg/hour titrated to gastric pH &gt;4.0 for prophylaxis or &gt;7.0 for treatment;",
"     <b>",
"      continuous I.V. infusion is preferred in patients with active bleeding",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erosive esophagitis: Oral: 150 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pathologic hypersecretory conditions (eg, Zollinger-Ellison syndrome):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion: Initial 50 mg I.V. followed by 1 mg/kg/hour infusion; titrate dosage in 0.5 mg/kg/hour increments to maintain gastric acid output at &lt;10 mEq/hour; doses up to 2.5 mg/kg/hour (220 mg/hour) have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 150 mg twice daily; more frequent administration may be indicated depending upon response; doses up to 6.3 g/day have been used in severe cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relief of heartburn, acid indigestion, sour stomach (OTC use): Oral: 75 mg 30-60 minutes before eating; no more than 2 tablets/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults (Aronoff, 1999):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Reduce dose to 50% of dose recommended for indication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Reduce dose to 25% of dose recommended for indication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"     as an alternative per manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 150 mg every 24 hours; adjust dose cautiously if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 50 mg every 18-24 hours; adjust dose cautiously if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Adjust dose schedule to administer dose at the end of dialysis",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in 1/2 NS [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg;: 50 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 25 mg/mL (2 mL, 6 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg;: 25 mg/mL (2 mL, 6 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 15 mg/mL (1 mL, 5 mL, 10 mL, 120 mL, 473 mL, 474 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg;: 15 mg/mL (480 mL) [contains ethanol 7.5%; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 75 mg, 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 150&reg;: 150 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 150&reg;: 150 mg [DSC] [cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 150&reg;: 150 mg [sodium free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 150&reg;: 150 mg [sodium free, sugar free; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 75&reg;: 75 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 75&reg;: 75 mg [sodium free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac 75&reg;: 75 mg [DSC] [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg;: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for solution, oral [effervescent]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zantac&reg; EFFERdose&reg;: 25 mg [contains phenylalanine 2.81 mg/tablet, sodium 30.52 mg (1.33 mEq)/tablet, sodium benzoate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes effervescent tablet, premixed infusion",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with meals and at bedtime; dissolve 25 mg EFFERdose&reg; tablet in 5 mL of water until completely dissolved; dissolve 150 mg EFFERdose&reg; tablet or granules in 6-8 ounces of water before administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Intermittent I.V. infusion preferred over direct injection to decrease risk of bradycardia; for intermittent infusion, infuse over 15-30 minutes, at a usual concentration of 0.5 mg/mL; for direct I.V. injection, administer over a period of at least 5 minutes, not to exceed 10 mg/minute (4 mL/minute) at a final concentration not to exceed 2.5 mg/mL; For I.M., administer undiluted (25 mg/mL)",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14473103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.5 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F217380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, fat emulsion 10%, LR, NS, sodium bicarbonate 5%; for injection, do not add other medications to premixed bag;",
"     <b>",
"      variable compatibility (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alcohol (ethyl), aldesleukin, allopurinol, amifostine, aminophylline, amsacrine, anidulafungin, atracurium, aztreonam, bivalirudin, cefazolin, cefepime, cefoxitin, ceftazidime, ciprofloxacin, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, diltiazem, dobutamine, docetaxel, dopamine, doripenem, doxapram, doxorubicin, doxorubicin liposome, enalaprilat, epinephrine, esmolol, etoposide phosphate, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, furosemide, gallium nitrate, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, idarubicin, labetalol, linezolid, lorazepam, melphalan, meperidine, methotrexate, midazolam, milrinone, morphine, nicardipine, nitroglycerin, norepinephrine, ondansetron, ondansetron with paclitaxel, oxaliplatin, paclitaxel, pancuronium, pemetrexed, piperacillin, piperacillin/tazobactam, procainamide, propofol, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, theophylline, thiopental, thiotepa, tigecycline, vecuronium, vinorelbine, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, hetastarch in sodium chloride 0.9%, insulin (regular), pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Drotrecogin alfa, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, dexamethasone sodium phosphate, dimenhydrinate, diphenhydramine, dobutamine, dopamine, fentanyl, glycopyrrolate, heparin, hydromorphone, meperidine, metoclopramide, morphine, nalbuphine, oxymorphone, pentazocine, prochlorperazine edisylate, promethazine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Hydroxyzine, methotrimeprazine, midazolam, pantoprazole, pentobarbital, phenobarbital.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Chlorpromazine, diazepam, lorazepam.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect injection from light; stable for 48 hours at room temperature or 30 days when frozen in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; stable for 24 hours in TPN solutions; stable for 24 hours in 3-in-1 total nutrient admixture",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of active duodenal ulcers and benign gastric ulcers; long-term prophylaxis of duodenal ulcer and gastric hypersecretory states; gastroesophageal reflux disease (GERD); recurrent postoperative ulcer; treatment and prophylaxis of erosive esophagitis; upper GI bleeding, prevention of acid-aspiration pneumonitis during surgery, and prevention of stress-induced ulcers; over-the-counter (OTC) formulation for use in the relief of heartburn, acid indigestion, and sour stomach",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F217382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ranitidine may be confused with amantadine, rimantadine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zantac&reg; may be confused with Xanax&reg;, Zarontin&reg;, Zofran&reg;, ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F217379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Asystole, atrioventricular block, bradycardia (with rapid I.V. administration), premature ventricular beats, tachycardia, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, dizziness, depression, hallucinations, headache, insomnia, malaise, mental confusion, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema multiforme, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Prolactin levels increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort/pain, constipation, diarrhea, nausea, necrotizing enterocolitis (VLBW neonates; Guillet, 2006), pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Acquired immune hemolytic anemia, acute porphyritic attack, agranulocytosis, aplastic anemia, granulocytopenia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic hepatitis, hepatic failure, hepatitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Transient pain, burning or itching at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, involuntary motor disturbance, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute interstitial nephritis, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pneumonia (causal relationship not established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, angioneurotic edema, hypersensitivity reactions (eg, bronchospasm, fever, eosinophilia)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ranitidine or any component or other H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists; patients with history of acute porphyria (may precipitate an acute attack)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with liver and renal impairment; dosage modification required in patients with renal impairment. Zantac&reg; 150 EFFERdose&reg; tablets and Zantac&reg; 150 EFFERdose&reg; granules contain phenylalanine; use with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of gastric acid inhibitors, including proton pump inhibitors and H",
"     <sub>",
"      2",
"     </sub>",
"     blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H",
"     <sub>",
"      2",
"     </sub>",
"     receptor antagonists; however, a causal relationship with ranitidine has not been demonstrated. Rapid I.V. administration of ranitidine has been associated with bradycardia, particularly in patients predisposed to cardiac rhythm disturbances. A cohort analysis including over 11,000 neonates reported an association of H",
"     <sub>",
"      2",
"     </sub>",
"     blocker use and an increased incidence of NEC in VLBW neonates (Guillet, 2006). An ~sixfold  increase in mortality, NEC, and infection (ie, sepsis, pneumonia, UTI) was reported in patients receiving ranitidine in a cohort analysis of 274 VLBW neonates (Terrin, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Zantac&reg; EFFERdose&reg; tablets and granules contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F217367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: H2-Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: H2-Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: H2-Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: H2-Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: H2-Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: H2-Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: H2-Antagonists may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: H2-Antagonists may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: H2-Antagonists may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: H2-Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): H2-Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: H2-Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: H2-Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): H2-Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: H2-Antagonists may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and the H2 receptor antagonist by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: H2-Antagonists may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: H2-Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: Ranitidine may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Ranitidine may increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: H2-Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: H2-Antagonists may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Ranitidine may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: H2-Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: H2-Antagonists may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Ranitidine may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal studies; therefore, ranitidine is classified as pregnancy category B. Ranitidine crosses the placenta. An increased risk of congenital malformations or adverse events in the newborn has generally not been observed following maternal use of ranitidine during pregnancy. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD) as well as gastric and duodenal ulcers during pregnancy. If needed, ranitidine is the agent of choice. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists may be used for aspiration prophylaxis prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     AST, ALT, serum creatinine; when used to prevent stress-related GI bleeding, measure the intragastric pH and try to maintain pH &gt;4; gastric acid secretion (&lt;10 mEq/hour)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1061783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum level necessary to inhibit basal acid secretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 90% suppression: 40-60 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 50% suppression: 36-94 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibition of histamine at H",
"     <sub>",
"      2",
"     </sub>",
"     -receptors of the gastric parietal cells, which inhibits gastric acid secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Minimally penetrates the blood-brain barrier; breast milk to plasma ratio: 1.9-6.7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 1-1.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 1.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: &sim;50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 90% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates (receiving ECMO): 6.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3.5-16 years: 1.8-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Normal renal and hepatic function: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Decreased renal function (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-35 mL/minute): 4.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 30% (oral) or 70% (I.V.) eliminated as unchanged drug in the urine and in feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis: Slightly dialyzable (5% to 20%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/56/22405?source=see_link\">",
"      see \"Ranitidine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid excessive amounts of coffee and aspirin; when self-medicating, if symptoms of heartburn, acid indigestion, or sour stomach persist after 2 weeks of continuous use of the drug, consult a clinician.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1061789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes fewer CNS adverse reactions and drug interactions compared to cimetidine; safety and efficacy of full-dose therapy extending beyond 8 weeks have not been determined; Zantac&reg; EFFERdose&reg; 150 mg tablets and granules contain 7.55 mEq sodium",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, Rothstein FC, Kaplan BS, et al, &ldquo;Pharmacokinetic Determination of Ranitidine Pharmacodynamics in Pediatric Ulcer Disease,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 107(2):301-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33815/abstract-text/4020560/pubmed\" id=\"4020560\" target=\"_blank\">",
"        4020560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33815/abstract-text/16651285/pubmed\" id=\"16651285\" target=\"_blank\">",
"        16651285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eddleston JM, Booker PD, and Green JR, &ldquo;Use of Ranitidine in Children Undergoing Cardiopulmonary Bypass,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1989, 17(1):26-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33815/abstract-text/ 2909317 /pubmed\" id=\" 2909317 \" target=\"_blank\">",
"        2909317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fontana M, Massironi E, Rossi A, et al, &ldquo;Ranitidine Pharmacokinetics in Newborn Infants,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1993, 68(5 Spec No):602-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33815/abstract-text/8323366/pubmed\" id=\"8323366\" target=\"_blank\">",
"        8323366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guillet R, Stoll BJ, Cotten CM, et al, \"Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(2):137-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33815/abstract-text/16390920/pubmed\" id=\"16390920\" target=\"_blank\">",
"        16390920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Herce J, Albajara L, Codoceo R, et al, &ldquo;Ranitidine Prophylaxis in Acute Gastric Mucosal Damage in Critically Ill Pediatric Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1988, 16(6):591-93.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris DL, Markham SJ, Beechey A, et al, &ldquo;Ranitidine-Bolus or Infusion Prophylaxis for Stress Ulcer,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1988, 16(3):229-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33815/abstract-text/3277779/pubmed\" id=\"3277779\" target=\"_blank\">",
"        3277779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts CJ, &ldquo;Clinical Pharmacokinetics of Ranitidine,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1984, 9(3):211-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33815/abstract-text/6329583 /pubmed\" id=\"6329583 \" target=\"_blank\">",
"        6329583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Terrin G, Passariello A, De Curtis M, et al, \"Ranitidine Is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(1):40-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/1/33815/abstract-text/22157140/pubmed\" id=\"22157140\" target=\"_blank\">",
"        22157140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12759 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-322217C268-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33815=[""].join("\n");
var outline_f33_1_33815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217321\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217322\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061780\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444951\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061772\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217292\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217276\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061785\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473103\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217380\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061776\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061784\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217382\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217379\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061788\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061771\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061770\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217367\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217285\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217288\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217302\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061779\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061783\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061769\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061787\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061778\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061789\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12759\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12759|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=related_link\">",
"      Ranitidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/56/22405?source=related_link\">",
"      Ranitidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_1_33816="Bulimia nervosa and binge eating disorder in adults: Medical complications and their management";
var content_f33_1_33816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bulimia nervosa and binge eating disorder in adults: Medical complications and their management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/1/33816/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/1/33816/contributors\">",
"     James E. Mitchell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/1/33816/contributors\">",
"     Christie Zunker, PhD, CPH, CHES",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/1/33816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/1/33816/contributors\">",
"     Joel Yager, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/1/33816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/1/33816/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/1/33816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27959295\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical complications and symptoms of poor health are common in patients with bulimia nervosa (BN) and binge eating disorder (BED) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As an example, an epidemiologic study found that somatic symptoms such as shortness of breath, chest pain, joint pain, gastrointestinal problems, menstrual problems, and headache occurred in significantly more patients with either BN or BED compared with patients who had no psychiatric disorder. &nbsp;",
"   </p>",
"   <p>",
"    The medical complications of BN and BED and their management are reviewed here. The epidemiology, pathogenesis, clinical features, treatment, and outcome are discussed separately, as are the medical complications of anorexia nervosa.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=see_link\">",
"       \"Eating disorders: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34841?source=see_link\">",
"       \"Binge-eating disorder: Overview of treatment in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27959861\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27959302\">",
"    <span class=\"h2\">",
"     Bulimia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;BN is marked by episodes of binge eating. In addition, there are inappropriate compensatory behaviors to prevent weight gain, including self-induced vomiting; misuse of laxatives, diuretics, or enemas; excessive exercise; fasting; or strict diets (",
"    <a class=\"graphic graphic_table graphicRef70006 \" href=\"mobipreview.htm?2/46/2796\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/3\">",
"     3",
"    </a>",
"    ]. The definition of BN is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link&amp;anchor=H4#H4\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\", section on 'Bulimia nervosa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27959309\">",
"    <span class=\"h2\">",
"     Binge eating disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;BED is characterized by episodes of binge eating, without the inappropriate compensatory behaviors that are seen in bulimia nervosa. The definition of BED is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34841?source=see_link&amp;anchor=H130122329#H130122329\">",
"     \"Binge-eating disorder: Overview of treatment in adults\", section on 'Definition of binge-eating disorder (BED)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H338058\">",
"    <span class=\"h1\">",
"     MEDICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical evaluation should pursue symptoms and signs of the medical complications described below. In addition, all patients with BN should receive a basic panel of laboratory tests, and additional tests as indicated by findings from the history and physical examination. Patients with medical complaints due to BN often attempt to hide their eating disorder from clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The medical evaluation of patients with BED is the same as it is for patients in the general population, and is guided by the medical status of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H338179\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common medical symptoms of BN are lethargy, irregular menses, abdominal pain and bloating, and constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H338186\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the context of a complete physical examination, key portions include weight and height; vital signs including heart rate, blood pressure both supine and standing, and temperature; skin; oropharyngeal; abdominal and neurologic examination (to look for other causes of weight loss or vomiting, eg, abdominal or central nervous system mass).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H338476\">",
"    <span class=\"h3\">",
"     Common physical signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common signs of BN are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tachycardia",
"     </li>",
"     <li>",
"      Hypotension (&lt; 90 mm Hg systolic)",
"     </li>",
"     <li>",
"      Xerosis (dry skin)",
"     </li>",
"     <li>",
"      Parotid gland swelling",
"     </li>",
"     <li>",
"      Erosion of dental enamel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other signs that are often present include hair loss, edema, and scarring or calluses on the dorsum of the hand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H338193\">",
"    <span class=\"h2\">",
"     Laboratory assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests should be guided by the symptoms and physical findings. Laboratory tests indicated for all patients with BN include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Blood urea nitrogen",
"     </li>",
"     <li>",
"      Serum creatinine",
"     </li>",
"     <li>",
"      Complete blood count including differential",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severely ill patients with BN warrant additional tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum calcium, magnesium, and phosphorous",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with suspected pancreatitis, clinicians should check serum amylase, fractionated for salivary gland isoenzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/7\">",
"     7",
"    </a>",
"    ]. Persistent amenorrhea should be investigated with luteinizing hormone, follicle-stimulating hormone, prolactin, and beta-human chorionic gonadotropin. Suspected laxative abuse can be assessed by checking stool or urine for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    , emodin, aloe-emodin, and rhein.",
"   </p>",
"   <p>",
"    No specific laboratory tests are indicated for patients with BED, unless they are obese and obesity-associated comorbidity is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27959316\">",
"    <span class=\"h1\">",
"     MEDICAL COMPLICATIONS OF BULIMIA NERVOSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical complications that occur in patients with BN affect many organ systems, and depend upon the method and frequency of purging, ie, self-induced vomiting or misuse of laxatives, diuretics, or enemas. Treatment for each complication includes discontinuation of purging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1013309\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal complications include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2,5,7-10\">",
"     2,5,7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Parotid and submandibular (salivary) gland hypertrophy, with puffy or swollen cheeks",
"     </li>",
"     <li>",
"      Loss of gag reflex",
"     </li>",
"     <li>",
"      Esophageal dysmotility",
"     </li>",
"     <li>",
"      Abdominal pain and bloating",
"     </li>",
"     <li>",
"      Heme-stained emesis",
"     </li>",
"     <li>",
"      Mallory-Weiss syndrome (esophageal tears)",
"     </li>",
"     <li>",
"      Esophageal rupture (Boerhaaves&rsquo; syndrome)",
"     </li>",
"     <li>",
"      Gastroesophageal reflux disease (GERD)",
"     </li>",
"     <li>",
"      Gastric dilation",
"     </li>",
"     <li>",
"      Diarrhea and malabsorption",
"     </li>",
"     <li>",
"      Steatorrhea",
"     </li>",
"     <li>",
"      Protein-losing gastroenteropathy",
"     </li>",
"     <li>",
"      Hypokalemic ileus",
"     </li>",
"     <li>",
"      Colonic dysmotility",
"     </li>",
"     <li>",
"      Constipation",
"     </li>",
"     <li>",
"      Melanosis coli",
"     </li>",
"     <li>",
"      Cathartic colon",
"     </li>",
"     <li>",
"      Pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of vomiting and right upper quadrant pain includes biliary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ]. An ultrasound can exclude the presence of gallstones. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link\">",
"     \"Approach to the patient with incidental gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Swollen parotid and submandibular glands usually do not require treatment, and should decrease in size over several months. For patients with pain due to swollen glands, treatment includes applying hot packs to the glands and sucking on hard candy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ]. If this is not successful, then oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    should be prescribed to stimulate salivary flow, at a dose of 5 mg two to three times per day. Bilateral gland enlargement due to purging should be distinguished from unilateral parotitis, which involves a bacterial infection and requires antibiotic medication.",
"   </p>",
"   <p>",
"    Diagnosis and management of GERD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of diarrhea and malabsorption are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22279?source=see_link\">",
"     \"Overview of the treatment of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis and treatment of protein-losing gastroenteropathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of ileus secondary to hypokalemia is discussed separately. (See",
"    <a class=\"local\" href=\"#H181909061\">",
"     'Renal and electrolytes'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment options for constipation include six to eight glasses of water per day; exercise; and 10 gram of fiber per day, one to three tablespoons of polyethylene glycol powder per day, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Patients should avoid high-dose, bulking, fiber-containing laxatives or stimulant laxatives that contain",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    , cascara, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    , which will worsen constipation. In addition, patients who misuse laxatives in an effort to lose weight should be educated that laxatives act upon the colon, after caloric absorption has occurred. Additional information about the evaluation and management of chronic constipation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link\">",
"     \"Etiology and evaluation of chronic constipation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pancreatitis may develop in patients who abuse alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ]. A review of 25 studies found that among patients with BN, 23 percent met criteria for alcohol abuse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, pancreatitis can occur in patients with BN who do not abuse alcohol or who have been abstinent from alcohol for many years; the etiology is unclear and not necessarily related to vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/12\">",
"     12",
"    </a>",
"    ]. Treatment of pancreatitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1013580\">",
"    <span class=\"h3\">",
"     Mallory-Weiss syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forceful vomiting may cause longitudinal mucosal lacerations in the distal esophagus and proximal stomach. Patients with the Mallory-Weiss syndrome may vomit bright red blood along with gastric contents. A complete rupture of the esophageal wall (Boerhaaves&rsquo; syndrome) is very rare, but extremely dangerous. The rupture usually appears in the lower chest, causes intense pain and contamination of the mediastinum and lungs, and requires immediate emergency care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis and treatment of the Mallory-Weiss syndrome and Boerhaave&rsquo;s syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43317?source=see_link\">",
"     \"Mallory-Weiss syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29606?source=see_link\">",
"     \"Boerhaave's syndrome: Effort rupture of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181909061\">",
"    <span class=\"h2\">",
"     Renal and electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of BN related to electrolyte imbalances include (",
"    <a class=\"graphic graphic_table graphicRef53037 \" href=\"mobipreview.htm?29/44/30411\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dehydration",
"     </li>",
"     <li>",
"      Hypokalemia",
"     </li>",
"     <li>",
"      Hypochloremia",
"     </li>",
"     <li>",
"      Metabolic alkalosis (because of volume contraction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other complications include hypomagnesemia, hypophosphatemia, and hyponatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine screening detects an electrolyte abnormality in 10 percent of patients with BN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/5\">",
"     5",
"    </a>",
"    ]. Hypokalemia may cause muscle weakness, cardiac arrhythmias, and impair renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To correct an electrolyte abnormality, it is usually sufficient to discontinue the purging behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/5\">",
"     5",
"    </a>",
"    ]. Management of electrolyte abnormalities is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9366?source=see_link\">",
"       \"Evaluation of the patient with hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link\">",
"       \"Clinical manifestations and treatment of hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11254?source=see_link\">",
"       \"Evaluation and treatment of hypomagnesemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=see_link\">",
"       \"Diagnosis and treatment of hypophosphatemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=see_link\">",
"       \"Treatment of metabolic alkalosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181909093\">",
"    <span class=\"h3\">",
"     Dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dehydration can cause volume depletion, with symptoms of dizziness and orthostasis. Treatment includes replenishing intravascular fluid with saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ]. For inpatients, intravenous normal saline should be used. Caution must be exercised to avoid edema. For outpatients, salt cubes in water or chicken broth should be ingested, starting with three cups per day and increasing as needed. The goal is to increase output of lighter-colored urine, increase venous jugular pressure, and eliminate postural changes in pulse and blood pressure. Additional information about rehydration is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link&amp;anchor=H8#H8\">",
"     \"Maintenance and replacement fluid therapy in adults\", section on 'Replacement fluid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27959323\">",
"    <span class=\"h2\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac complications are rare in patients with BN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ]. Complications include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypotension and orthostasis",
"     </li>",
"     <li>",
"      Sinus tachycardia",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Edema",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG) changes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Depressed ST segment",
"     </li>",
"     <li>",
"      QT prolongation",
"     </li>",
"     <li>",
"      Widened QRS complex",
"     </li>",
"     <li>",
"      Increased P-wave amplitude",
"     </li>",
"     <li>",
"      Increased PR interval",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Supraventricular and ventricular ectopic rhythm",
"     </li>",
"     <li>",
"      Torsade de pointes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If QT prolongation is present, clinicians should avoid medications that prolong the QT",
"    <sub>",
"     c",
"    </sub>",
"    interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of cardiovascular complications includes correcting any associated cause, eg, hypokalemia or volume depletion. If complications persist despite corrective measures, or if complications are accompanied by chest pain, shortness of breath, dizziness, or loss of consciousness, a cardiology consult should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1012918\">",
"    <span class=\"h2\">",
"     Ipecac-induced myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ipecac syrup is an over-the-counter emetic that some patients with BN ingest to induce vomiting. A case series of 661 patients with BN found that nine percent chronically abused ipecac [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/13\">",
"     13",
"    </a>",
"    ]. Chronic use damages muscle cells including the myocardium, which may lead to cardiomyopathy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147223174\">",
"    <span class=\"h3\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;One component of ipecac is emetine, which accumulates in cardiac muscle cells and is toxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. Emetine is eliminated from the body slowly, and has been detected in urine 60 days after chronic use. Signs and symptoms of cardiotoxicity include precordial chest pain, dyspnea, hypotension, supraventricular tachycardia, atrial premature contractions, flattened or inverted T waves, prolonged QT and PR intervals, ventricular tachycardia and fibrillation, cardiac failure, pericardial effusion, pulmonary congestion, and cardiac arrest.",
"   </p>",
"   <p>",
"    Small, chronic doses have caused cumulative, fatal toxicity in a few patients. The lethal chronic dose is not known. Absorption of emetine is enhanced in patients who become refractory to the emetic effects of the drug during chronic misuse. &nbsp;",
"   </p>",
"   <p>",
"    Patients suspected of chronic ipecac abuse should receive a cardiology consult. Treatment includes discontinuation of ipecac and supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/9\">",
"     9",
"    </a>",
"    ]. No specific antidote or pharmacologic antagonist for the cardiotoxic effects of emetine exists, and patients may die despite intensive care. Recovery may be prolonged (eg, months) because emetine is slowly eliminated from the body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337797\">",
"    <span class=\"h3\">",
"     Skeletal muscle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic abuse of ipecac may damage skeletal muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/7,9,13\">",
"     7,9,13",
"    </a>",
"    ]. Symptoms include generalized weakness, especially in the neck and proximal muscles of the extremities; myalgia and tenderness; hyporeflexia; slurred speech; dysphagia; and difficulty with tasks requiring muscular activity (eg, climbing stairs). Ipecac-induced myopathy is associated with elevated liver function tests, nonspecific abnormalities on an electromyographic (EMG) recording, and abnormal muscle biopsy. Normal muscular activity is slowly restored following discontinuation of ipecac. Chronic ipecac abuse and subsequent cardiac myopathy are both discussed separately. (See",
"    <a class=\"local\" href=\"#H1012918\">",
"     'Ipecac-induced myopathy'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11906795\">",
"    <span class=\"h2\">",
"     Endocrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrine complications of BN involve the reproductive and skeletal systems, and there may be an association between BN and diabetes. Severe complications can occur in patients with BN and comorbid diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common endocrine complication involves the reproductive system. Among 82 women treated for BN, menstrual irregularities were present in 45 percent at pretreatment and in 31 percent at 12 month follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/15\">",
"     15",
"    </a>",
"    ]. By contrast, an epidemiologic study of 403 healthy, premenopausal women aged 18 to 39 years found that 5 percent had anovulatory menstrual cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/16\">",
"     16",
"    </a>",
"    ]. Signs and symptoms of reproductive system complications include impaired fertility, spotty and scanty menstrual periods, oligomenorrhea, or amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BN may be associated with diabetes. An epidemiologic study of 4651 females, treated in primary care or obstetric gynecology settings, found that diabetes was present in significantly more patients with BN compared with patients who had no eating disorder (9 versus 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/17\">",
"     17",
"    </a>",
"    ]. Conversely, a meta-analysis of eight case-controlled studies (748 female patients with type 1 diabetes and 1587 nondiabetic females) found that the prevalence of BN was significantly higher in the diabetic patients compared with the nondiabetic patients (1.73 versus 0.69 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/18\">",
"     18",
"    </a>",
"    ]. Diagnosis and treatment of diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteopenia and osteoporosis may be more common in BN, particularly in patients who have had previous episodes of anorexia nervosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/7\">",
"     7",
"    </a>",
"    ]. Management of osteoporosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroid function is usually normal in BN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ]. A study compared 75 bulimic women with 64 healthy control women and found similar values for free T4 and free T3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1013501\">",
"    <span class=\"h2\">",
"     Dental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric acid in vomitus softens and erodes dental enamel, which may cause sensitivity to hot and cold temperatures in food and drinks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ]. Some patients exhibit decalcification of the teeth (perimylolysis), particularly on the lingual, palatal, and posterior occlusal surfaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/4\">",
"     4",
"    </a>",
"    ]. Teeth may also become discolored, and caries and gum disease may occur.",
"   </p>",
"   <p>",
"    Enamel loss can be reduced by instructing patients to wash out their mouth after vomiting, gargle with baking soda in water to alkalinize their mouth, wait at least 30 minutes before brushing their teeth, and use alkaline toothpaste [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ]. Hot and cold foods and liquids should be limited as needed to avoid pain. Acidic foods (eg, fruit and yogurt) should also be limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/5\">",
"     5",
"    </a>",
"    ]. Chewing sugarless gum is recommended to increase salivary flow. In addition, a dentist should be consulted for restorative procedures after purging is controlled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H338694\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nearly pathognomonic dermatologic complication is scarring or calluses on the dorsum of the hand (Russell&rsquo;s sign; due to pressure of the teeth against the skin while stimulating the gag reflex to induce vomiting) (",
"    <a class=\"graphic graphic_picture graphicRef52728 \" href=\"mobipreview.htm?35/27/36287\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. A study of 122 patients with BN detected this sign in 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/20\">",
"     20",
"    </a>",
"    ]. Xerosis, poor skin turgor, petechia, telogen effluvium, and acne may also be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Self-injurious behavior is common in BN, and patients may show acute or chronic signs of trauma from cuts or burns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27959344\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other medical complications include fluctuation of body weight, vitamin deficiencies, aspiration pneumonitis, and conjunctival hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2,7,9\">",
"     2,7,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27959351\">",
"    <span class=\"h1\">",
"     MEDICAL COMPLICATIONS OF BINGE EATING DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BED often describe somatic symptoms and dissatisfaction with health. However, there is little evidence of medical complications that can be directly attributed to binge-eating symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/17,22,23\">",
"     17,22,23",
"    </a>",
"    ]. One study suggests hypercholesterolemia is associated with BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study of 59 obese women with a lifetime history of binge eating and 107 obese women without binge eating compared the prevalence of self-reported hypertension, cardiac problems, diabetes (type 1 or 2), osteoarthritis, asthma, visual impairment, or any major medical disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with binge eating reported higher rates of each disorder, although the differences did not reach statistical significance.",
"   </p>",
"   <p>",
"    An epidemiologic study found that joint pain, headache, gastrointestinal problems, menstrual problems, shortness of breath, and chest pain each occurred in significantly more patients with BED than patients without psychiatric disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/17\">",
"     17",
"    </a>",
"    ]. However, somatic symptoms do not necessarily equate with medical complications. Another finding was that significantly more patients with BED described their general health as poor or very poor, compared with patients free of psychiatric disorders (7 versus 1 percent), but the association of BED with poor health was not significant when the analyses controlled for comorbid mood disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27959358\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with BED are obese and suffer the medical complications associated with obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The complications of obesity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not clear if BED is associated with medical complications beyond those observed in obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2,4,23\">",
"     2,4,23",
"    </a>",
"    ]. Several studies show higher rates of gastrointestinal, cardiovascular, pulmonary, and rheumatologic disorders or symptoms in obese patients with BED compared to obese patients without BED, but the differences are generally not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112487493\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;BED does not appear to be associated with diabetes. In an observational study, 134 patients with BED were matched for age, sex, and body mass index with 134 individuals with no history of an eating disorder. Over five years of follow-up, the incidence of new-onset type 2 diabetes was similar for subjects with and without BED (10 versus 8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/22\">",
"     22",
"    </a>",
"    ]. Although an epidemiologic study of patients treated in primary care and obstetric gynecology settings found that diabetes was present in significantly more patients with BED compared with patients who had no eating disorder (6 versus 3 percent), the comparison did not control for body mass index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies indicate that BED or binge eating do not significantly affect glycemic control in type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis and treatment of diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181908231\">",
"    <span class=\"h2\">",
"     Hypercholesterolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An observational study of patients with BED matched for body mass index with individuals with no eating disorder found that hypercholesterolemia occurred in significantly more patients with BED (30 versus 17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33816/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261027664\">",
"    <span class=\"h1\">",
"     HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain medical complications require inpatient treatment on an internal medicine, psychiatric, or combined ward. The choice depends upon the patient&rsquo;s medical and psychiatric status, and available resources. Criteria for inpatient treatment and principles of management in this setting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=see_link&amp;anchor=H17#H17\">",
"     \"Eating disorders: Treatment\", section on 'Criteria for hospitalization'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/37/26194?source=see_link\">",
"       \"Patient information: Bulimia nervosa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27959449\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BN is marked by episodes of binge eating. In addition, there are inappropriate compensatory behaviors to prevent weight gain, including self-induced vomiting; misuse of laxatives, diuretics, or enemas; excessive exercise; fasting; or strict diets (",
"      <a class=\"graphic graphic_table graphicRef70006 \" href=\"mobipreview.htm?2/46/2796\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link&amp;anchor=H4#H4\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\", section on 'Bulimia nervosa'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      BED is characterized by episodes of binge eating, without the inappropriate compensatory behaviors that are seen in bulimia nervosa. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34841?source=see_link&amp;anchor=H130122329#H130122329\">",
"       \"Binge-eating disorder: Overview of treatment in adults\", section on 'Definition of binge-eating disorder (BED)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common medical symptoms of BN are lethargy, irregular menses, abdominal pain and bloating, and constipation. (See",
"      <a class=\"local\" href=\"#H338179\">",
"       'Medical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Within the context of a complete physical examination, key portions include weight and height; vital signs including heart rate, blood pressure both supine and standing, and temperature; skin; oropharyngeal; abdominal and neurologic examination to evaluate for other causes of weight loss or vomiting. Common signs of bulimia nervosa are tachycardia, hypotension, xerosis, parotid gland swelling, and erosion of dental enamel. (See",
"      <a class=\"local\" href=\"#H338186\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal complications include parotid and submandibular gland hypertrophy; loss of gag reflex; abdominal pain, bloating and dilatation; Mallory-Weiss syndrome, gastroesophageal reflux disease (GERD); diarrhea and malabsorption; constipation; and colonic dysmotility. (See",
"      <a class=\"local\" href=\"#H1013309\">",
"       'Gastrointestinal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common renal and electrolyte complications include dehydration, hypokalemia, hypochloremia, and metabolic alkalosis. (See",
"      <a class=\"local\" href=\"#H181909061\">",
"       'Renal and electrolytes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac complications are rare. Complications observed in patients with BN include hypotension and orthostasis, sinus tachycardia, palpitations, edema, electrocardiogram changes, and arrhythmia. (See",
"      <a class=\"local\" href=\"#H27959323\">",
"       'Cardiac'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ipecac is used by some patients with BN to induce vomiting, and chronic abuse may cause cardiomyopathy and damage skeletal muscle. (See",
"      <a class=\"local\" href=\"#H1012918\">",
"       'Ipecac-induced myopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H337797\">",
"       'Skeletal muscle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endocrine complications of BN involve the reproductive and skeletal systems, and there may be an association between BN and diabetes. (See",
"      <a class=\"local\" href=\"#H11906795\">",
"       'Endocrine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dental complications of BN include erosion of dental enamel, decalcification and discoloration of the teeth, caries, and gum disease. (See",
"      <a class=\"local\" href=\"#H1013501\">",
"       'Dental'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dermatologic complications include scarring or calluses on the dorsum of the hand (Russell&rsquo;s sign) (",
"      <a class=\"graphic graphic_picture graphicRef52728 \" href=\"mobipreview.htm?35/27/36287\">",
"       picture 1",
"      </a>",
"      ), xerosis, poor skin turgor, petechia, telogen effluvium, and acne. In addition, patients with self-injurious behavior will show acute or chronic signs of trauma from cuts or burns. (See",
"      <a class=\"local\" href=\"#H338694\">",
"       'Skin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with BED often describe somatic symptoms and dissatisfaction with health. However, there is little evidence of medical complications that can be directly attributed to binge-eating symptoms. (See",
"      <a class=\"local\" href=\"#H27959351\">",
"       'Medical complications of binge eating disorder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/1\">",
"      Mitchell JE, Crow S. Medical complications of anorexia nervosa and bulimia nervosa. Curr Opin Psychiatry 2006; 19:438.",
"     </a>",
"    </li>",
"    <li>",
"     Mehler, PS, Birmingham, LC, Crow, SJ, Jahraus, JP. Medical complications of eating disorders. In: The Treatment of Eating Disorders: A Clinical Handbook, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.66.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, 2000. p.594.",
"    </li>",
"    <li>",
"     Mitchell, JE, Crow, SJ. Medical comorbidities of eating disorders. In: The Oxford Handbook of Eating Disorders, Agras, WS (Eds), Oxford University Press, New York 2010. p.259.",
"    </li>",
"    <li>",
"     Eating Disorders: Core Interventions in the Treatment of and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders. National Institute for Clinical Excellence, Clinical Guideline 9. file://guidance.nice.org.uk (Accessed on December 22, 2010).",
"    </li>",
"    <li>",
"     Mehler, PS, Anderson, AE. Eating Disorders: A guide to medical care and complications, 2nd ed, The Johns Hopkins University Press, Baltimore, MD 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/7\">",
"      American Psychiatric Association. Treatment of patients with eating disorders,third edition. American Psychiatric Association. Am J Psychiatry 2006; 163:4.",
"     </a>",
"    </li>",
"    <li>",
"     Pomeroy, C, Mitchell, JE, Roerig, J, Crow, S. Medical Complications of Psychiatric Illness, American Psychiatric Publishing, Inc., Washington, DC 2002.",
"    </li>",
"    <li>",
"     American Society of Health-System Pharmacists. AHFS Drug Information 2008, American Society of Helath-System Pharmacists, American Hospital Formulary Service, Bethesda, MD 2008. p.2990.",
"    </li>",
"    <li>",
"     Halmi, K. Eating disorders: Anorexia nervosa, bulimia nervosa, and obesity. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales, RE, Yudofsky, SC, Gabbard GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/11\">",
"      Holderness CC, Brooks-Gunn J, Warren MP. Co-morbidity of eating disorders and substance abuse review of the literature. Int J Eat Disord 1994; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/12\">",
"      Morris LG, Stephenson KE, Herring S, Marti JL. Recurrent acute pancreatitis in anorexia and bulimia. JOP 2004; 5:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/13\">",
"      Greenfeld D, Mickley D, Quinlan DM, Roloff P. Ipecac abuse in a sample of eating disordered outpatients. Int J Eat Disord 1993; 13:411.",
"     </a>",
"    </li>",
"    <li>",
"     Ipecac syrup: Drug information file://uptodate.com (Accessed on October 29, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/15\">",
"      Gendall KA, Bulik CM, Joyce PR, et al. Menstrual cycle irregularity in bulimia nervosa. Associated factors and changes with treatment. J Psychosom Res 2000; 49:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/16\">",
"      Waller K, Swan SH, Windham GC, et al. Use of urine biomarkers to evaluate menstrual function in healthy premenopausal women. Am J Epidemiol 1998; 147:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/17\">",
"      Johnson JG, Spitzer RL, Williams JB. Health problems, impairment and illnesses associated with bulimia nervosa and binge eating disorder among primary care and obstetric gynaecology patients. Psychol Med 2001; 31:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/18\">",
"      Mannucci E, Rotella F, Ricca V, et al. Eating disorders in patients with type 1 diabetes: a meta-analysis. J Endocrinol Invest 2005; 28:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/19\">",
"      Monteleone P, Santonastaso P, Pannuto M, et al. Enhanced serum cholesterol and triglyceride levels in bulimia nervosa: relationships to psychiatric comorbidity, psychopathology and hormonal variables. Psychiatry Res 2005; 134:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/20\">",
"      Glorio R, Allevato M, De Pablo A, et al. Prevalence of cutaneous manifestations in 200 patients with eating disorders. Int J Dermatol 2000; 39:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/21\">",
"      Strumia R. Dermatologic signs in patients with eating disorders. Am J Clin Dermatol 2005; 6:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/22\">",
"      Hudson JI, Lalonde JK, Coit CE, et al. Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder. Am J Clin Nutr 2010; 91:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33816/abstract/23\">",
"      Bulik CM, Sullivan PF, Kendler KS. Medical and psychiatric morbidity in obese women with and without binge eating. Int J Eat Disord 2002; 32:72.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14728 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33816=[""].join("\n");
var outline_f33_1_33816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27959449\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27959295\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27959861\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27959302\">",
"      Bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27959309\">",
"      Binge eating disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H338058\">",
"      MEDICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H338179\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H338186\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H338476\">",
"      - Common physical signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H338193\">",
"      Laboratory assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27959316\">",
"      MEDICAL COMPLICATIONS OF BULIMIA NERVOSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1013309\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1013580\">",
"      - Mallory-Weiss syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181909061\">",
"      Renal and electrolytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181909093\">",
"      - Dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27959323\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1012918\">",
"      Ipecac-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H147223174\">",
"      - Cardiac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H337797\">",
"      - Skeletal muscle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11906795\">",
"      Endocrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1013501\">",
"      Dental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H338694\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27959344\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27959351\">",
"      MEDICAL COMPLICATIONS OF BINGE EATING DISORDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27959358\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112487493\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181908231\">",
"      Hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261027664\">",
"      HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27959449\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14728\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14728|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/27/36287\" title=\"picture 1\">",
"      Russells sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14728|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/46/2796\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/44/30411\" title=\"table 2\">",
"      Serum electrolyte levels usually associated with purging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/48/2830\" title=\"table 3\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34841?source=related_link\">",
"      Binge-eating disorder: Overview of treatment in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29606?source=related_link\">",
"      Boerhaave's syndrome: Effort rupture of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=related_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9366?source=related_link\">",
"      Evaluation of the patient with hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43317?source=related_link\">",
"      Mallory-Weiss syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22279?source=related_link\">",
"      Overview of the treatment of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/37/26194?source=related_link\">",
"      Patient information: Bulimia nervosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_1_33817="Prevention and treatment of lymphedema";
var content_f33_1_33817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of lymphedema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/1/33817/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/1/33817/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/1/33817/contributors\">",
"     Tammy E Mondry, DPT, MSRS, CLT-LANA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/1/33817/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/1/33817/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/1/33817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/1/33817/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/1/33817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema is due to an abnormality in the lymphatic system, often involves one limb, and is generally irreversible. Lymphedema is generally classified as primary (hereditary) or secondary (acquired), which is much more common (",
"    <a class=\"graphic graphic_table graphicRef64677 \" href=\"mobipreview.htm?4/47/4859\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three categories of primary lymphedema: congenital lymphedema, lymphedema praecox, and lymphedema tarda.",
"     </li>",
"     <li>",
"      The causes of secondary lymphedema include interruption of lymphatics by surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy, malignant obstruction, and infection. Lymph node dissection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation for breast cancer or melanoma are the most common causes in developed countries, while filariasis is the most common cause worldwide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevention and treatment of lymphedema will be reviewed here. Much of the discussion will focus on lymphedema in breast cancer patients, which is the focus of much of the medical literature. The etiology, clinical manifestations, and diagnosis of lymphedema are presented separately, as is the operative management of primary and secondary lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29177?source=see_link\">",
"     \"Operative management of primary and secondary lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTIVE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with breast cancer, we recommend sentinel node biopsy (SNB) in all women eligible for this procedure for axillary staging because compared to axillary node dissection (AND), it has been shown to effectively reduce the risk of lymphedema. There are no other published randomized controlled trials that demonstrate the efficacy of one mode of prevention over another or even establish the efficacy of prophylactic measures over no such measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prevention measures, such as axillary lymph node staging with SNB instead of an AND, have been most successful in breast cancer patients. However, the use of SNB in the staging of other malignancies, such as melanoma, cervical, and vulvar cancers, may also decrease the risk of developing lymphedema in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Sentinel lymph node biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=see_link&amp;anchor=H261294268#H261294268\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Extent of dissection and morbidity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20714?source=see_link\">",
"     \"Vulvar cancer: Staging, treatment, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In breast cancer, axillary lymph node staging with SNB has reduced the number of AND performed and consequently the incidence of lymphedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Clinically relevant lymphedema occurs in 5 to 9 percent of patients who undergo SNB alone as compared to about 40 percent in patients undergoing ALND. Other modalities may also be effective for the primary prevention of lymphedema. These include minimizing the extent of lymph node dissections, advanced radiation therapy (RT) techniques, and new surgical techniques, such as axillary reverse mapping and lymphatic bypass procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper body exercise is safe in women treated by AND and evidence supports use of prophylactic physiotherapy to prevent lymphedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. In a single blinded clinical trial, 116 women after unilateral breast surgery with ALND were randomly assigned to education and early physiotherapy (manual lymph drainage [MLD], massage of scar tissue, and progressive active and action assisted shoulder exercises) or education alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/7\">",
"     7",
"    </a>",
"    ]. After 12 months of follow-up, significantly fewer women treated with early physiotherapy developed lymphedema (16 versus 25 percent with education alone). However, in another study involving 156 patients, all received guidelines about the prevention of lymphedema and exercise therapy with randomization to treatment with MLD or no other therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/13\">",
"     13",
"    </a>",
"    ]. At 12 months, those who received the MLD had a higher incidence of lymphedema compared to those who did not undergo MLD (24 versus 19 percent). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Manual lymphatic drainage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Limb exercise with weights",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resistance devices is",
"    <strong>",
"     not",
"    </strong>",
"    recommended during the immediate recovery phase of lymph node surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT, because the increase in blood flow may worsen the edema. However, exercises to restore the full range of motion in affected extremities are generally recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14\">",
"     14",
"    </a>",
"    ]. Exercise may also be beneficial in patients with established lymphedema. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Exercise'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with breast cancer, Cancer and Leukemia Group B trial 70305 (CALGB 70305) is testing whether an intervention aimed at improving arm function (which includes lymphedema education, the use of light arm weights with exercises, light compression sleeves during vigorous arm use, and regular breathing exercises) can reduce the incidence and severity of arm or hand lymphedema in breast cancer patients who have undergone an AND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Prevention and prophylactic treatments of lymphedema secondary to infection, in particular, cellulitis and lymphatic filariasis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15241?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of lymphatic filariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link&amp;anchor=H13#H13\">",
"     \"Cellulitis and erysipelas\", section on 'Recurrent cellulitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of general measures aimed at both minimizing the degree of edema and slowing the rate of progression. Although there is no scientific evidence supporting the efficacy of any of these measures, we agree with the guidelines from the National Lymphedema Network and suggest the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be taught how to monitor their lymphedema, including measurement of size. They should be counselled to report any changes in size, sensation, color, temperature, or skin condition promptly. &nbsp;",
"     </li>",
"     <li>",
"      Meticulous skin hygiene and nail care should be maintained to prevent a portal of entry for infection that may result in cellulitis. Exposed skin should be protected, including use of sunscreen and wearing of gloves while doing activities that may cause skin injury. Patients should be encouraged to use skin moisturizers and topical antibiotic solutions after small breaks in the skin as may be induced by a paper cut or abrasions, pinpricks, insect bites, or pet scratches.",
"     </li>",
"     <li>",
"      Exercise and weight training should be performed, with a properly fitted compression garment worn during exercise. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Exercise'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      All episodes of cellulitis should be treated. If patients experience three or more episodes of cellulitis in a year, we suggest an extended period of oral antibiotic therapy.",
"     </li>",
"     <li>",
"      Patients should NOT maintain the limb in a gravity-dependent position for long periods of time; this includes prolonged standing, sitting, or crossing legs.",
"     </li>",
"     <li>",
"      Tight-fitting clothing should be avoided in the affected limb, since it might cause a tourniquet-effect and obstruct lymph flow. On the other hand, fitted and graded compression sleeves may reduce the degree of lymphedema. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Compression garments'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Whenever possible, patients should avoid medical procedures, such as vaccination, acupuncture, phlebotomy, intravenous lines, and venography, in the affected limb.",
"     </li>",
"     <li>",
"      Avoid exposure to temperature extremes, which may increase the risk of injury to the tissue in the lymphedematous limb. In addition, lymphedema may be exacerbated in patients who use saunas, steam baths, or hot tubs.",
"     </li>",
"     <li>",
"      Maintenance of ideal body weight should be encouraged; besides being a contributory factor for the development of lymphedema, obesity may also limit the effectiveness of compression pumps or sleeves [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there are no data confirming benefit, it is recommended that blood pressure be measured in the contralateral arm if the patient is having surgery or is in any other setting in which blood pressure is being closely monitored (eg, in an intensive care unit, recovery room, or during procedures). Measurement of arm blood pressure is not an issue if there has not been axillary node dissection (eg, patients who have undergone only a sentinel lymph node procedure without a full lymph node dissection, or women with prophylactic bilateral mastectomy without lymph node evaluation). Among the rare patients who have undergone bilateral axillary node dissection, routine blood pressure measurements can be obtained in the leg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link&amp;anchor=H10#H10\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\", section on 'Leg blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although in theory, lymphedema may be exacerbated at high altitude or during air travel since the ambient atmosphere pressure is less than the relative outlet transcapillary pressure within the superficial tissues, studies suggest that the risk from air travel of precipitating or worsening lymphedema is very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Whether the use of compression sleeves during air flight in women with lymphedema is of benefit is debated. Some suggest that domestic air travel (&lt;4.5 hours) is low risk and that compression devices may be counterproductive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/23\">",
"     23",
"    </a>",
"    ]. For longer duration air travel, compression garments, exercises, and self-massage may all be helpful. It is important to note that compression devices may lead to the onset or progression of lymphedema when they are restrictive or not properly fitted. When correctly fitted and worn properly, compression garments may reduce the risk of swelling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema is often difficult to treat, particularly if not diagnosed at an early stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/25\">",
"     25",
"    </a>",
"    ]. The goal of therapy is to control limb swelling since the underlying disease cannot usually be corrected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14,19,26-28\">",
"     14,19,26-28",
"    </a>",
"    ]. Measurements of limb circumference",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    volume are common methods for monitoring the degree of lymphedema during and after therapy, particularly arm edema in patients with breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H857615700#H857615700\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Clinical measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and treatment of breast cancer treatment-related lymphedema at a very early stage may provide for more conservative intervention while potentially preventing the lymphatic condition from progressing into a chronic stage. This was demonstrated in a case-control study of 196 breast cancer patients, in which a surveillance program that included preoperative limb volume measurement and interval postoperative follow-up was able to detect subclinical lymphedema, reduce affected limb volume with early treatment (with a compression sleeve and gauntlet), and maintain this volume reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If left untreated, lymphedema tends to gradually progress over time and inhibit the activities of daily living [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/30\">",
"     30",
"    </a>",
"    ]. Nonpharmacologic modalities are used since no drugs have been shown to be beneficial. In particular, as will be described below, diuretics should not be given. These nonpharmacologic measures are best performed in clinics with expertise in the treatment of lymphedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/1,31\">",
"     1,31",
"    </a>",
"    ]. Treatment usually consists of a multimodality regimen including exercise, skin care, compression bandaging compression garments, manual therapy, and, in some cases, external sequential pneumatic compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14,19,26\">",
"     14,19,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with lymphedema following breast cancer surgery, a search for concomitant disorders should be pursued when there is massive lymphedema that is refractory to usual therapies or has an onset several years after the primary surgery without obvious trauma. In particular, recurrence of the breast cancer in the axillary area or the development of lymphangiosarcoma should be excluded by use of computed tomography or magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/2,3,32\">",
"     2,3,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complete decongestive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach to lymphedema is largely dependent upon physiotherapeutic techniques. The term complete decongestive therapy (CDT, also called complex decongestive therapy, complex decongestive physiotherapy or decongestive lymphatic therapy) refers to an empirically derived, multicomponent technique that is designed to reduce the degree of lymphedema and to maintain the health of the skin and supporting structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14,19,26\">",
"     14,19,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Phases",
"    </span>",
"    &nbsp;&mdash;&nbsp;CDT generally consists of a two-phase treatment program that can be used in both adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14,19,26\">",
"     14,19,26",
"    </a>",
"    ]. Success is dependent in part upon the availability of physicians, nurses, and physical therapists that are trained in these techniques.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first phase (treatment phase) includes meticulous skin and nail care to prevent infection, therapeutic exercise, a massage-like technique called manual lymph drainage, and limb compression using repetitively applied, multilayered padding materials and short-stretch bandages. The patients receive daily therapy five days per week, with circumference and volume measurements weekly to see if improvement is continuing or the patient has plateaued [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19\">",
"       19",
"      </a>",
"      ]. The usual duration of the first stage is two to four weeks.",
"     </li>",
"     <li>",
"      The second phase (maintenance phase) is intended to conserve and optimize the benefit attained in the first phase. It consists of compression garments worn during waking hours and, if necessary, self-compression bandaging at night, skin care, continued exercises, and, as necessary, self-manual lymph drainage. Limb circumference and volume measurements should be monitored every six months or sooner if necessary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H802881735#H802881735\">",
"       \"Clinical manifestations and diagnosis of lymphedema\", section on 'Circumferential measurements'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy of CDT has been suggested in observational studies, which demonstrated a reduction in limb volume with improved pain, cosmesis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. In these studies, the reduction in limb volume ranged from 33 to 68 percent. Patient compliance is required for long-term success. In one study, at least 90 percent of the lymphedema reduction was maintained in compliant patients at an average follow-up of nine months, while noncompliant patients lost approximately one-third of the initial benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/33\">",
"     33",
"    </a>",
"    ]. The benefit of CDT was shown in a small phase III trial in which 53 patients with lymphedema after breast cancer treatment were randomly assigned to CDT (lymph drainage, multilayer compression bandaging, elevation, remedial exercise and skin care) versus standard physiotherapy (bandages, elevation, head-neck and shoulder exercises and skin care) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/38\">",
"     38",
"    </a>",
"    ]. The group receiving CDT had a significantly greater improvement in edema as measured by circumferential and volumetric measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experts have described several possible contraindications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    precautions to CDT, and in particular to manual lymphatic drainage (MLD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14,19,39\">",
"     14,19,39",
"    </a>",
"    ]. Although these contraindications are commonly followed, they are predominantly based upon theoretical concerns and there is little clinical data to support them. As an example, the 2003 International Society of Lymphology consensus statement listed active neoplasia in the affected limb as a contraindication, but the theoretic concept that massage promotes metastases is debated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19\">",
"     19",
"    </a>",
"    ]. A retrospective review found that patients with locoregional disease as compared to those without experienced similar benefit from CDT and no study has ever demonstrated that massage therapy spreads cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following conditions have been listed as possible contraindications to therapy. We suggest that consideration of CDT or MLD in such patients should be under the guidance of a trained lymphologist and clinician.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active cellulitis, neoplasm, or other inflammations of the infected limb (CDT may spread the infection or exacerbate symptoms).",
"     </li>",
"     <li>",
"      Moderate to severe heart failure (which may be exacerbated by the increase in central venous volume induced by mobilization of the lymphatic fluid).",
"     </li>",
"     <li>",
"      Acute deep vein thrombosis (since embolism may result from dislodging of clot).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications, such that patients may be treated but may warrant monitoring, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncontrolled hypertension (which may be exacerbated by the increase in central venous blood volume caused by MLD and compression bandaging). In this case, the patient's cardiac functions are monitored during the treatment phase.",
"     </li>",
"     <li>",
"      Diabetes mellitus (since associated vasculopathy or neuropathy may decrease the sensing of pain with improperly fitting compression garments, possibly leading to tissue injury and infection).",
"     </li>",
"     <li>",
"      Asthma (since parasympathetic activation can occur, possibly promoting an asthma attack). With these patients the manual lymphatic drainage (MLD) treatment time should begin at approximately 20 minutes and if no negative reactions are noted, the treatment time should be increased 5 to 10 minutes until normal treatment times are reached [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paralysis (since a flaccid limb may offer insufficient resistance when compression bandages and garments are used and, any decrease in sensation may promote injury from improperly fitting compression garments).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Manual lymphatic drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manual techniques are typically included as a component of complete decongestive therapy (CDT). Manual lymphatic drainage (MLD) is a massage-like technique that is performed by specially trained physical therapists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14,19,26,27\">",
"     14,19,26,27",
"    </a>",
"    ]. With MLD, light pressure is used to mobilize edema fluid from distal to proximal areas in an attempt to enhance filling of the cutaneous lymph vessels, promote dilation and contractility of lymphatic conduits, and recruit watershed pathways for lymph flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/26\">",
"     26",
"    </a>",
"    ]. Lymphatic drainage may also be promoted by gentle therapeutic exercise of the affected limb. Contraindications to MLD are described above. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Supportive data for the efficacy of MLD come from observational studies and from the use of MLD within a CDT regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/35,41-43\">",
"     35,41-43",
"    </a>",
"    ]. The few available randomized trials had a small number of patients and conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Benefit was noted in a randomized crossover trial of 31 women with lymphedema following breast cancer treatment in which MLD reduced the excess limb volume more than simple lymphatic drainage (a modified version of MLD taught to patients for the self-management of lymphedema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast, no benefit was noted in a trial of 42 women with lymphedema following breast cancer treatment who were randomly assigned to standard therapy (compression garments, physical exercises, and education) with or without a short course of MLD (eight session in two weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/45\">",
"     45",
"    </a>",
"    ]. Both groups had a similar reduction in lymphedema volume.",
"   </p>",
"   <p>",
"    Despite the relatively poor quality of the evidence supporting its use, MLD is typically included in CDT and is recommended as part of such a multimodality regimen in the 2003 consensus statement from the International Society of Lymphology and in subsequent reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14,19,26\">",
"     14,19,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After completion of the program, patients should wear compression garments during waking hours and as necessary, perform self-compression bandaging of the limb at night. When possible, patients and family members should be instructed on self-MLD techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Compression bandaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial stages of lymphedema management, external compression to diminish ultrafiltration is achieved with repetitively applied, multilayered padding materials and short-stretch (also called low-stretch) bandages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19,26,47\">",
"     19,26,47",
"    </a>",
"    ]. The compression bandaging is applied to the affected limb after MLD is performed and is worn 24 hours per day during the treatment phase (phase 1) of CDT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Phases'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Short-stretch bandages apply pressure during movement, but not at rest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19\">",
"     19",
"    </a>",
"    ]. The pressure induced by muscle contraction within the bandage appears to reduce lymphedema via mechanical stimulation of the smooth muscle of the lymphatic vessels, resulting in increased lymph flow. The multilayered bandage may also soften the edematous tissue, thereby increasing the efficacy of MLD.",
"   </p>",
"   <p>",
"    Once the lymphedema reaches its nadir, maintenance therapy begins which includes fitted compression garments during waking hours. Some patients also require nocturnal compression with a nighttime garment. These garments consist of padding materials with compression applied over the padding with short stretch bandages, elastic sleeves, or Velcro. The compression garments need to be fitted appropriately and replaced every three to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of this approach was illustrated in a randomized trial of 90 women with unilateral lymphedema that compared the use of multilayered short-stretch bandaging for 18 days followed by elastic hosiery for 24 weeks to the use of elastic hosiery alone for 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/47\">",
"     47",
"    </a>",
"    ]. Combined therapy was approximately twice as effective in reducing limb volume (31 versus 16 percent at 24 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible alternative to standard bandages is kinesio tape (also called K-tape), which is made of a highly elastic woven fabric that stretches only along its longitudinal axis and has been used for rehabilitation after sports injuries. An initial randomized trial of 41 patients with breast cancer and unilateral lymphedema of the arm found equivalent efficacy with K-tape and short-stretch bandages but better patient acceptance of K-tape, manifested by less difficulty in usage and increased comfort and convenience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Compression garments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fitted elastic knit two-way stretch compression garments (lymphedema compression sleeve and gauntlet or stocking) generate greater pressures distally than proximally, thereby promoting mobilization of the edema fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14,19,26,28\">",
"     14,19,26,28",
"    </a>",
"    ]. These garments, which come in compression classes that have designated medical indications deliver 20 to 50+ mmHg of pressure, and are used during the maintenance phase (phase 2) of CDT to prevent fluid reaccumulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19,26\">",
"     19,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Phases'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Compression garments are typically worn during waking hours, with compression bandaging at night, if necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19\">",
"     19",
"    </a>",
"    ]. It is important to ensure that the garment does not increase edema in any area of the limb.",
"   </p>",
"   <p>",
"    A custom-made garment may be necessary if prefabricated garments do not fit properly. However, as fluid shifts occur, even custom-made garments may no longer fit. The garments should be replaced every three to six months or when they lose elasticity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/26\">",
"     26",
"    </a>",
"    ]. Use of compression garments during exercise is discussed below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Exercise'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of exercise or its avoidance during post-surgical recovery in the primary prevention of lymphedema is discussed above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Primary prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with lymphedema, participation in sports involving repetitive movements against resistance, such as rowing, tennis, or golf, has traditionally been discouraged. However, there is accumulating evidence of the safety of exercise and weight training in the affected limb and of other benefits associated with exercise, such as improvements in cardiovascular fitness and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/49-53\">",
"     49-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefits of exercise were illustrated in a randomized controlled trial of twice-weekly progressive weight lifting over a one year period (supervised for the first 13 weeks) in 141 breast cancer survivors with stable lymphedema of the arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/52\">",
"     52",
"    </a>",
"    ]. Weight lifting did not enhance the frequency of a 5 percent or more increase in limb swelling (11 versus 12 percent in controls), reduced the number and severity of arm and hand symptoms, increased muscular strength, and significantly reduced the incidence of lymphedema exacerbations (14 versus 29 percent).",
"   </p>",
"   <p>",
"    A properly fitted compression garment should be worn during exercise, including aerobic and resistive training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In the study described above supporting the potential benefits of a slowly progressive weight lifting program in women with breast cancer-related lymphedema, the exercise was performed in conjunction with appropriate use of compression garments and close monitoring for arm and hand swelling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Lymphedema Network position statement for exercise recommends that individuals with lymphedema have adequate compression in the form of compression bandages or garments, while individuals at risk for developing lymphedema may consider obtaining a compression garment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/55\">",
"     55",
"    </a>",
"    ]. The compression garments should be measured and fitted by an individual trained and experienced in fitting compression garments.&nbsp;The garments should be at least a Class I compression for upper extremity support. A compression hand piece, either a glove or a gauntlet, is necessary when wearing a compression sleeve to prevent swelling in the hand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple elevation of a lymphedematous limb may reduce swelling, particularly in the early stage of lymphedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14\">",
"     14",
"    </a>",
"    ]. However, elevation alone is not an effective long-term therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intermittent pneumatic compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent pneumatic compression (also called sequential pneumatic compression) is another method of compression therapy in patients with lymphedema. These devices employ a plastic sleeve or stocking that is intermittently inflated over the affected limb. Most pneumatic compression pumps sequentially inflate a series of chambers in a distal-to-proximal direction. Some pumps permit adjustment of the amount of pressure in a particular chamber. After external compression therapy is applied, a form-fitting, low-stretch elastic knit sleeve is usually applied to maintain edema reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have evaluated the role of intermittent pneumatic compression (IPC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/41,57-61\">",
"     41,57-61",
"    </a>",
"    ]. A randomized trial demonstrated that this modality has no role as sole therapy for lymphedema, since it was not significantly more effective than prophylactic hygienic care alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, IPC may be an effective addition to a multimodality lymphedema treatment regimen. This was illustrated in a trial of 11 patients with unilateral previously untreated breast cancer-associated lymphedema who were randomly assigned to CDT alone or with adjunctive IPC (30 minutes daily for 10 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/57\">",
"     57",
"    </a>",
"    ]. Combined therapy was associated with a significantly greater reduction in limb volume during initial treatment (45 versus 26 percent with CDT alone).",
"   </p>",
"   <p>",
"    A second arm of the trial evaluated the efficacy of maintenance IPC therapy (self-administered 60 minutes daily) added to CDT in 11 patients with unilateral breast cancer-associated lymphedema who had previously been treated with CDT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/57\">",
"     57",
"    </a>",
"    ]. At 6 to 12 months, mean limb volume fell with combined therapy compared to an increase with CDT alone (-90 versus +33 mL), a difference that was statistically significant.",
"   </p>",
"   <p>",
"    In addition to the paucity of data demonstrating benefit from IPC, there are a number of concerns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ideal pressure for the pump is not known, and some investigators suggest that a pressure greater than 60 mmHg may injure lymphatic vessels.",
"     </li>",
"     <li>",
"      IPC is usually applied daily or five times per week. However, the optimal duration of IPC is not known as, in different studies, the sessions have varied length (90 minutes to as long as six hours) and duration (two to three days to four weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/47,57-61\">",
"       47,57-61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, IPC may be considered as an adjunct in patients who do respond well to CDT and compression garments. If the lymphedema is controlled with IPC, a gradient pressure garment should be worn to prevent further limb swelling. Clinical experience has shown that IPC may be an alternative maintenance program for lymphedema patients that have difficulty in performing self-MLD secondary to weakness, fatigue, or range of motion deficits. It may also be beneficial for lymphedema patients that are unable to utilize compression bandaging or garments due to skin allergies from the materials used in these compression products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is NO chronic pharmacologic therapy recommended for patients with lymphedema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics are usually of little benefit in chronic lymphedema and may promote the development of volume depletion. When diuretics are given to treat the usual forms of peripheral edema, the initial fluid loss comes from the intravascular space. The ensuing reduction in venous and, therefore, intracapillary pressure allows the edema fluid to be mobilized and the plasma volume to be maintained. However, this sequence does not occur with lymphatic obstruction since the edema fluid cannot be easily mobilized into the vascular space. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=see_link\">",
"     \"Clinical manifestations and diagnosis of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Coumarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial report found that coumarin (a warfarin-like drug that might reduce high protein edema by stimulating proteolysis) was beneficial in patients with lymphedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/62\">",
"     62",
"    </a>",
"    ]. However, a larger, carefully performed crossover study of 140 women found no difference between coumarin and placebo in reducing arm volume and relieving symptoms; coumarin was also associated with significant hepatotoxicity in 6 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/63\">",
"     63",
"    </a>",
"    ]. A subsequent systematic review concluded that the poor quality of the trials prevented any conclusions about the effectiveness of benzopyrones (including coumarin) in reducing limb volume, pain, or discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics that have adequate coverage for gram-positive cocci should be promptly administered for a cellulitic infection. Severe cellulitis, lymphangitis, or bacteremia require intravenous antibiotics. Oral antibiotic therapy may be continued for extended periods of time in patients with chronic infection or for those who experience more than three episodes of cellulitis per year. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary surgical method for treating lymphedema consists of removing the subcutaneous fat and fibrous tissue (reduction operation or liposuction) with or without creation of a dermal flap within the muscle to encourage superficial to deep lymphatic anastomoses. Case series suggest only modest outcomes, including decreased limb volume, increased activity, and improved quality of life, with surgical reduction for both primary and secondary lymphedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. However, many patients regress to preoperative girth measurements three to four years following surgery.",
"   </p>",
"   <p>",
"    Skin necrosis is a recognized surgical morbidity which may result in both prolonged hospitalization and time loss from work. Thus, this procedure should be considered only in patients in whom physical interventions have failed to control limb swelling.",
"   </p>",
"   <p>",
"    An alternative approach is lymphatic microsurgery in which the lymph is drained into the venous circulation or the lymphatic collectors above the area of lymphatic obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19\">",
"     19",
"    </a>",
"    ]. There has been only a limited experience with this technique in specialized centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Furthermore, a 2009 literature review of 11 procedures in 10 patients found only a minimal reduction in lymphedema volume (5 percent at three months and 2 percent at one year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Low-level laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-level laser therapy (also known as cold laser therapy) is a photochemical treatment used for soft tissue injury, chronic pain, and wound healing. Two small randomized trials in women with postmastectomy lymphedema have shown a reduction in limb volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]; two others failed to show any benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Among the hypotheses to explain the possible benefits of laser therapy include a potential decrease in fibrosis, stimulation of macrophages and the immune system, and a suggested role in encouraging lymphangiogenesis, which may both stimulate surviving lymphatic pathways and encourage the formation of new pathways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Weight reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity can exacerbate breast cancer related lymphedema, and thus, weight reduction has been recommended in its management. The effects of weight reduction on changes in excess arm volume was studied in a trial of twenty-one patients with breast cancer-related lymphedema who were randomly assigned to receive dietary advice for weight reduction or to receive a booklet on general healthy eating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/18\">",
"     18",
"    </a>",
"    ]. At the end of the 12-week study, the weight reduction group as compared to the control-group experienced a significant reduction in body weight, body mass index, and excess arm volume. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H802872652#H802872652\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy to develop new lymphangioles in the affected limbs is a potential clinical remedy in the future. The potential efficacy of this approach was illustrated in a mouse model with lymphedema due to an inactivating VEGFR-3 mutation, similar to that in congenital hereditary lymphedema (Milroy disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/1/33817/abstract/76\">",
"     76",
"    </a>",
"    ]. Virus mediated therapy with the gene for VEGF-C, which activates VEGFR-3, led to the generation of functional lymphatic vessels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H40511035#H40511035\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/1/24594?source=see_link\">",
"       \"Patient information: Lymphedema after breast cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/32/15876?source=see_link\">",
"       \"Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there are numerous measures commonly believed to be important for the prevention of lymphedema and several available treatment options, there is little evidence to support efficacy or to compare the benefit of one modality to another.",
"     </li>",
"     <li>",
"      For patients with cancer, sentinel lymph node biopsy has been instrumental in decreasing the incidence of lymphedema. This has been most widely demonstrated in women undergoing treatment for breast cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Primary prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several secondary prevention measures, mainly aimed at prevention of infection and avoidance of constriction and injury of the affected limb, which may offer benefit in reducing lymphedema risk. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Secondary prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with lymphedema and no contraindications, we suggest initiating therapy for lymphedema with complete decongestive therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Complete decongestive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with lymphedema, we suggest limb exercise, including range of motion and weight lifting, typically combined with limb compression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not usually prescribe diuretics for patients with lymphedema because edema fluid cannot be easily mobilized into the vascular space. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/1\">",
"      Tunkel RS, Lachmann E. Lymphedema of the limb. An overview of treatment options. Postgrad Med 1998; 104:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/2\">",
"      Stewart FW, Treves N. Classics in oncology: lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. CA Cancer J Clin 1981; 31:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/3\">",
"      Tomita K, Yokogawa A, Oda Y, Terahata S. Lymphangiosarcoma in postmastectomy lymphedema (Stewart-Treves syndrome): ultrastructural and immunohistologic characteristics. J Surg Oncol 1988; 38:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/4\">",
"      Nos C, Kaufmann G, Clough KB, et al. Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol 2008; 15:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/5\">",
"      Cheville AL, Das I, Srinivas S, et al. A pilot study to assess the utility of SPECT/CT-based lymph node imaging to localize lymph nodes that drain the arm in patients undergoing treatment for breast cancer. Breast Cancer Res Treat 2009; 116:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/6\">",
"      Boccardo FM, Casabona F, Friedman D, et al. Surgical prevention of arm lymphedema after breast cancer treatment. Ann Surg Oncol 2011; 18:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/7\">",
"      Torres Lacomba M, Yuste S&aacute;nchez MJ, Zapico Go&ntilde;i A, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ 2010; 340:b5396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/8\">",
"      Chan DN, Lui LY, So WK. Effectiveness of exercise programmes on shoulder mobility and lymphoedema after axillary lymph node dissection for breast cancer: systematic review. J Adv Nurs 2010; 66:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/9\">",
"      McNeely ML, Campbell K, Ospina M, et al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev 2010; :CD005211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/10\">",
"      Schmitz KH, Ahmed RL, Troxel AB, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA 2010; 304:2699.",
"     </a>",
"    </li>",
"    <li>",
"     Devoogdt N, Christiaens M-R, Geraerts I, et al. Is Manual Lymph Drainage Applied after Axillary Lymph Node Dissection for Breast Cancer Effective To Prevent Arm Lymphoedema? A Randomised Controlled Trial. Abstract S5-3, presented at the 33rd Annual San Antonio Breast Conference, December 8-12, 2010. Available online at file://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_434&amp;terms= (Accessed on February 07, 2011).",
"    </li>",
"    <li>",
"     Schmitz KH, Cheville A, Ahmed RL, Troxel A. Balancing Risks of Deconditioning vs. Weight-Lifting for Breast Cancer Survivors.Abstract ES9-3, presented at the 33rd Annual San Antonio Breast Conference, December 8-12, 2010. Available online at file://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_9027&amp;terms= (Accessed on February 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/13\">",
"      Devoogdt N, Christiaens MR, Geraerts I, et al. Effect of manual lymph drainage in addition to guidelines and exercise therapy on arm lymphoedema related to breast cancer: randomised controlled trial. BMJ 2011; 343:d5326.",
"     </a>",
"    </li>",
"    <li>",
"     The diagnosis and treatment of peripheral lymphedema: 2003 consensus of the International Society of Lymphology Executive Committee www.u.arizona.edu/%7Ewitte/ISL.htm (Accessed on April 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/15\">",
"      Paskett ED. Breast cancer-related lymphedema: attention to a significant problem resulting from cancer diagnosis. J Clin Oncol 2008; 26:5666.",
"     </a>",
"    </li>",
"    <li>",
"     www.cancer.gov/clinicaltrials/CALGB-70305 (Accessed on April 19, 2011).",
"    </li>",
"    <li>",
"     Lymphedema Risk Reduction Practices file://www.lymphnet.org/pdfDocs/nlnriskreduction.pdf (Accessed on June 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/18\">",
"      Shaw C, Mortimer P, Judd PA. A randomized controlled trial of weight reduction as a treatment for breast cancer-related lymphedema. Cancer 2007; 110:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/19\">",
"      Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin 2009; 59:8.",
"     </a>",
"    </li>",
"    <li>",
"     National Lymphedema Network. Air travel www.lymphnet.org/pdfDocs/nlnairtravel.pdf (Accessed on April 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/21\">",
"      Kilbreath SL, Ward LC, Lane K, et al. Effect of air travel on lymphedema risk in women with history of breast cancer. Breast Cancer Res Treat 2010; 120:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/22\">",
"      Casley-Smith JR, Casley-Smith JR. Lymphedema initiated by aircraft flights. Aviat Space Environ Med 1996; 67:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/23\">",
"      Graham PH. Compression prophylaxis may increase the potential for flight-associated lymphoedema after breast cancer treatment. Breast 2002; 11:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/24\">",
"      Poage E, Singer M, Armer J, et al. Demystifying lymphedema: development of the lymphedema putting evidence into practice card. Clin J Oncol Nurs 2008; 12:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/25\">",
"      Erickson VS, Pearson ML, Ganz PA, et al. Arm edema in breast cancer patients. J Natl Cancer Inst 2001; 93:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/26\">",
"      Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol 2008; 52:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/27\">",
"      Rockson SG, Miller LT, Senie R, et al. American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Cancer 1998; 83:2882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/28\">",
"      Brennan MJ, Miller LT. Overview of treatment options and review of the current role and use of compression garments, intermittent pumps, and exercise in the management of lymphedema. Cancer 1998; 83:2821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/29\">",
"      Stout Gergich NL, Pfalzer LA, McGarvey C, et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 2008; 112:2809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/30\">",
"      Casley-Smith JR. Alterations of untreated lymphedema and it's grades over time. Lymphology 1995; 28:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/31\">",
"      Brennan MJ. Lymphedema following the surgical treatment of breast cancer: a review of pathophysiology and treatment. J Pain Symptom Manage 1992; 7:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/32\">",
"      Cozen W, Bernstein L, Wang F, et al. The risk of angiosarcoma following primary breast cancer. Br J Cancer 1999; 81:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/33\">",
"      Ko DS, Lerner R, Klose G, Cosimi AB. Effective treatment of lymphedema of the extremities. Arch Surg 1998; 133:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/34\">",
"      Boris M, Weindorf S, Lasinkski S. Persistence of lymphedema reduction after noninvasive complex lymphedema therapy. Oncology (Williston Park) 1997; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/35\">",
"      Szuba A, Cooke JP, Yousuf S, Rockson SG. Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema. Am J Med 2000; 109:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/36\">",
"      Hamner JB, Fleming MD. Lymphedema therapy reduces the volume of edema and pain in patients with breast cancer. Ann Surg Oncol 2007; 14:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/37\">",
"      Mondry TE, Riffenburgh RH, Johnstone PA. Prospective trial of complete decongestive therapy for upper extremity lymphedema after breast cancer therapy. Cancer J 2004; 10:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/38\">",
"      Didem K, Ufuk YS, Serdar S, Z&uuml;mre A. The comparison of two different physiotherapy methods in treatment of lymphedema after breast surgery. Breast Cancer Res Treat 2005; 93:49.",
"     </a>",
"    </li>",
"    <li>",
"     Zuther E. Pathology. In: Lymphedema Management: The Comprehensive Guide for Practitioners, Von Rohr M (Ed), Thieme Medical Publishers Inc, New York 2005. p.45.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/40\">",
"      Pinell XA, Kirkpatrick SH, Hawkins K, et al. Manipulative therapy of secondary lymphedema in the presence of locoregional tumors. Cancer 2008; 112:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/41\">",
"      Zanolla R, Monzeglio C, Balzarini A, Martino G. Evaluation of the results of three different methods of postmastectomy lymphedema treatment. J Surg Oncol 1984; 26:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/42\">",
"      Casley-Smith JR, Boris M, Weindorf S, Lasinski B. Treatment for lymphedema of the arm--the Casley-Smith method: a noninvasive method produces continued reduction. Cancer 1998; 83:2843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/43\">",
"      Leduc O, Leduc A, Bourgeois P, Belgrado JP. The physical treatment of upper limb edema. Cancer 1998; 83:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/44\">",
"      Williams AF, Vadgama A, Franks PJ, Mortimer PS. A randomized controlled crossover study of manual lymphatic drainage therapy in women with breast cancer-related lymphoedema. Eur J Cancer Care (Engl) 2002; 11:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/45\">",
"      Andersen L, H&oslash;jris I, Erlandsen M, Andersen J. Treatment of breast-cancer-related lymphedema with or without manual lymphatic drainage--a randomized study. Acta Oncol 2000; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/46\">",
"      Johansson K, Albertsson M, Ingvar C, Ekdahl C. Effects of compression bandaging with or without manual lymph drainage treatment in patients with postoperative arm lymphedema. Lymphology 1999; 32:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/47\">",
"      Badger CM, Peacock JL, Mortimer PS. A randomized, controlled, parallel-group clinical trial comparing multilayer bandaging followed by hosiery versus hosiery alone in the treatment of patients with lymphedema of the limb. Cancer 2000; 88:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/48\">",
"      Tsai HJ, Hung HC, Yang JL, et al. Could Kinesio tape replace the bandage in decongestive lymphatic therapy for breast-cancer-related lymphedema? A pilot study. Support Care Cancer 2009; 17:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/49\">",
"      Markes M, Brockow T, Resch KL. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev 2006; :CD005001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/50\">",
"      McKenzie DC, Kalda AL. Effect of upper extremity exercise on secondary lymphedema in breast cancer patients: a pilot study. J Clin Oncol 2003; 21:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/51\">",
"      Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized controlled trial of weight training and lymphedema in breast cancer survivors. J Clin Oncol 2006; 24:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/52\">",
"      Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med 2009; 361:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/53\">",
"      Sagen A, K&aring;resen R, Risberg MA. Physical activity for the affected limb and arm lymphedema after breast cancer surgery. A prospective, randomized controlled trial with two years follow-up. Acta Oncol 2009; 48:1102.",
"     </a>",
"    </li>",
"    <li>",
"     Moseley AL, Piller NB. Exercise for Limb Lymphoedema: Evidence that it is beneficial. J Lymphoedema 2008; 3:51.",
"    </li>",
"    <li>",
"     National Lymphedema Network. NLN position paper: Exercise for lymphedema patients. file://www.lymphnet.org/pdfDocs/nlnexercise.pdf (Accessed on December 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/56\">",
"      Swedborg I, Norrefalk JR, Piller NB, Asard C. Lymphoedema post-mastectomy: is elevation alone an effective treatment? Scand J Rehabil Med 1993; 25:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/57\">",
"      Szuba A, Achalu R, Rockson SG. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. Cancer 2002; 95:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/58\">",
"      Dini D, Del Mastro L, Gozza A, et al. The role of pneumatic compression in the treatment of postmastectomy lymphedema. A randomized phase III study. Ann Oncol 1998; 9:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/59\">",
"      Johansson K, Lie E, Ekdahl C, Lindfeldt J. A randomized study comparing manual lymph drainage with sequential pneumatic compression for treatment of postoperative arm lymphedema. Lymphology 1998; 31:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/60\">",
"      Richmand DM, O'Donnell TF Jr, Zelikovski A. Sequential pneumatic compression for lymphedema. A controlled trial. Arch Surg 1985; 120:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/61\">",
"      Pappas CJ, O'Donnell TF Jr. Long-term results of compression treatment for lymphedema. J Vasc Surg 1992; 16:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/62\">",
"      Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med 1993; 329:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/63\">",
"      Loprinzi CL, Kugler JW, Sloan JA, et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med 1999; 340:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/64\">",
"      Badger C, Preston N, Seers K, Mortimer P. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev 2004; :CD003140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/65\">",
"      Tiwari A, Cheng KS, Button M, et al. Differential diagnosis, investigation, and current treatment of lower limb lymphedema. Arch Surg 2003; 138:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/66\">",
"      Brorson H, Ohlin K, Olsson G, et al. Quality of life following liposuction and conservative treatment of arm lymphedema. Lymphology 2006; 39:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/67\">",
"      Brorson H, Ohlin K, Olsson G, et al. Controlled compression and liposuction treatment for lower extremity lymphedema. Lymphology 2008; 41:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/68\">",
"      Ogunbiyi SO, Modarai B, Smith A, et al. Quality of life after surgical reduction for severe primary lymphoedema of the limbs and genitalia. Br J Surg 2009; 96:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/69\">",
"      Campisi C, Eretta C, Pertile D, et al. Microsurgery for treatment of peripheral lymphedema: long-term outcome and future perspectives. Microsurgery 2007; 27:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/70\">",
"      Baumeister RG, Frick A. [The microsurgical lymph vessel transplantation]. Handchir Mikrochir Plast Chir 2003; 35:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/71\">",
"      Damstra RJ, Voesten HG, van Schelven WD, van der Lei B. Lymphatic venous anastomosis (LVA) for treatment of secondary arm lymphedema. A prospective study of 11 LVA procedures in 10 patients with breast cancer related lymphedema and a critical review of the literature. Breast Cancer Res Treat 2009; 113:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/72\">",
"      Carati CJ, Anderson SN, Gannon BJ, Piller NB. Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial. Cancer 2003; 98:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/73\">",
"      Kozanoglu E, Basaran S, Paydas S, Sarpel T. Efficacy of pneumatic compression and low-level laser therapy in the treatment of postmastectomy lymphoedema: a randomized controlled trial. Clin Rehabil 2009; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/74\">",
"      Kaviani A, Fateh M, Yousefi Nooraie R, et al. Low-level laser therapy in management of postmastectomy lymphedema. Lasers Med Sci 2006; 21:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/75\">",
"      Maiya AG, Olivia ED, Dibya A. Effect of low-level laser therapy in the management of postmastectomy lymphoedema. Physiotherapy Singapore 2008; 11:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/1/33817/abstract/76\">",
"      Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A 2001; 98:12677.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 738 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33817=[""].join("\n");
var outline_f33_1_33817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTIVE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complete decongestive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Phases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Manual lymphatic drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Compression bandaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Compression garments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intermittent pneumatic compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Coumarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Low-level laser therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Weight reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/738|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/47/4859\" title=\"table 1\">",
"      Causes of lymphedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15241?source=related_link\">",
"      Diagnosis, treatment, and prevention of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=related_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29177?source=related_link\">",
"      Operative management of primary and secondary lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/32/15876?source=related_link\">",
"      Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/1/24594?source=related_link\">",
"      Patient information: Lymphedema after breast cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20714?source=related_link\">",
"      Vulvar cancer: Staging, treatment, and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_1_33818="Bullous pemphigoid tense bullae";
var content_f33_1_33818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54541%7EDERM%2F70352%7EDERM%2F79112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54541%7EDERM%2F70352%7EDERM%2F79112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tense blisters in bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    &nbsp; Multiple tense bullae on inflamed skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple tense bullae on skin with one eroded blister base.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arm skin with tense bullae arising on urticarial plaques and eroded blister bases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33818=[""].join("\n");
var outline_f33_1_33818=null;
var title_f33_1_33819="Comparison of ventilation";
var content_f33_1_33819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Volume cycled versus pressure controlled ventilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Volume cycled",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Advantages",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Guaranteed tidal volume and VE",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Clinician familiarity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Disadvantages",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Airway pressures not controlled",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Worse patient tolerance",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pressure controlled",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Advantages",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Airway pressures controlled",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Better patient tolerance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Disadvantages",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Less clinician familiarity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            VT and VE not guaranteed",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33819=[""].join("\n");
var outline_f33_1_33819=null;
var title_f33_1_33820="Laboratory findings in vitamin D deficiency";
var content_f33_1_33820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Biochemical manifestations of different stages of vitamin D deficiency, as compared with deficiencies of calcium or phosphorus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plasma Ca",
"        <sup>",
"         ++",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plasma PO",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td class=\"subtitle1\">",
"        ALP",
"       </td>",
"       <td class=\"subtitle1\">",
"        PTH",
"       </td>",
"       <td class=\"subtitle1\">",
"        25(OH)-D",
"       </td>",
"       <td class=\"subtitle1\">",
"        1,25(OH)",
"        <sub>",
"         2",
"        </sub>",
"        -D",
"       </td>",
"       <td class=\"subtitle1\">",
"        X-ray changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Vitamin D deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Early",
"       </td>",
"       <td>",
"        N or &darr;",
"       </td>",
"       <td>",
"        N or &darr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        Osteopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderate",
"       </td>",
"       <td>",
"        N or &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &uarr;&uarr;",
"       </td>",
"       <td>",
"        &uarr;&uarr;",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        Rachitic changes +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        &uarr;&uarr;&uarr;",
"       </td>",
"       <td>",
"        &uarr;&uarr;&uarr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &uarr; or N or &darr;",
"       </td>",
"       <td>",
"        Rachitic changes ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Calcium deficiency",
"        </strong>",
"       </td>",
"       <td>",
"        N or &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &uarr;&uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Phosphorus deficiency",
"        </strong>",
"       </td>",
"       <td>",
"        N or &uarr;",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        &uarr;&uarr;",
"       </td>",
"       <td>",
"        N or &darr;",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N: normal; ALP: alkaline phosphatase; PTH: parathyroid hormone; 25(OH)D: 25-hydroxyvitamin D; 1,25(OH)",
"     <sub>",
"      2",
"     </sub>",
"     D: 1,25-dihydroxyvitamin D.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Levine MA, Zapalowski C, Kappy MS. Disorders of calcium, phosphate, parathyroid hormone, and Vitamin D. In: Kappy MS, Allen DB, and Geffner ME (Eds). Principles and Practice of Pediatric Endocrinology. Charles C. Thomas Co, Springfield, 2005.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33820=[""].join("\n");
var outline_f33_1_33820=null;
var title_f33_1_33821="Predictors DFS RT stage I-II HL";
var content_f33_1_33821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical stage I-II Hodgkin lymphoma: presentation variables and disease-free survival after radiotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variables",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relapse, percent DF at&nbsp;five years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Significance, log rank",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Male",
"       </td>",
"       <td>",
"        761",
"       </td>",
"       <td>",
"        68 percent",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Female",
"       </td>",
"       <td>",
"        603",
"       </td>",
"       <td>",
"        67 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;25 years",
"       </td>",
"       <td>",
"        375",
"       </td>",
"       <td>",
"        69 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        25 to 39 years",
"       </td>",
"       <td>",
"        472",
"       </td>",
"       <td>",
"        68 percent",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;39 years",
"       </td>",
"       <td>",
"        516",
"       </td>",
"       <td>",
"        66 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Histology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LP",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        79 percent",
"       </td>",
"       <td>",
"        p&lt;0.025",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NS",
"       </td>",
"       <td>",
"        836",
"       </td>",
"       <td>",
"        67 percent",
"       </td>",
"       <td>",
"        p&lt;0.025",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MC",
"       </td>",
"       <td>",
"        326",
"       </td>",
"       <td>",
"        64 percent",
"       </td>",
"       <td>",
"        p&lt;0.025",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LD",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        58 percent",
"       </td>",
"       <td>",
"        p&lt;0.025",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Number of sites involved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 site",
"       </td>",
"       <td>",
"        658",
"       </td>",
"       <td>",
"        72 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 sites",
"       </td>",
"       <td>",
"        416",
"       </td>",
"       <td>",
"        68 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 sites",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        55 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;3 sites",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        57 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Mediastinal status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uninvolved",
"       </td>",
"       <td>",
"        888",
"       </td>",
"       <td>",
"        70 percent",
"       </td>",
"       <td>",
"        p&lt;0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Involved",
"       </td>",
"       <td>",
"        470",
"       </td>",
"       <td>",
"        64 percent",
"       </td>",
"       <td>",
"        p&lt;0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        B symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absent",
"       </td>",
"       <td>",
"        1215",
"       </td>",
"       <td>",
"        70 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Present",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        52 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        ESR, mm/hour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;20",
"       </td>",
"       <td>",
"        498",
"       </td>",
"       <td>",
"        76 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20 to 30",
"       </td>",
"       <td>",
"        253",
"       </td>",
"       <td>",
"        66 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        40 to 59",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        61 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;60",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        53 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absent",
"       </td>",
"       <td>",
"        903",
"       </td>",
"       <td>",
"        70 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Present",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        54 percent",
"       </td>",
"       <td>",
"        p&lt;0.005",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LP: lymphocyte predominance; NS: nodular sclerosing; MC: mixed cellularity; LD: lymphocyte depletion; ESR: erythrocyte sedimentation rate.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Mauch PM, Armitage JO, Diehl V, et al. Hodgkin's Disease, Lippincott Williams &amp; Wilikins, Philadelphia 1999.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33821=[""].join("\n");
var outline_f33_1_33821=null;
var title_f33_1_33822="Relation cysteine atheroscler";
var content_f33_1_33822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Low and high plasma levels of total cysteine are associated with cerebrovascular and peripheral vascular disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 564px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The is a dose-response relation between total cysteine levels and odds ratio for cerebrovascular disease (panel B) and peripheral vascular disease (panel C), but not for coronary artery disease (panel A). Values are adjusted for age, sex, center, creatinine, smoking, diastolic blood pressure, homocysteine, body mass index, and cholesterol by use of generalized additive logistic regression. Solid line indicates estimated dose-response curve; gray area, 95 percent confidence interval.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: El-Khairy L, Ueland PM, Refsum H, et al. Circulation 2001; 103:2544.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33822=[""].join("\n");
var outline_f33_1_33822=null;
var title_f33_1_33823="List of affected facilities PI";
var content_f33_1_33823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Healthcare facilities that had contaminated steroid medicine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Healthcare facility",
"       </td>",
"       <td class=\"subtitle1\">",
"        Phone number",
"       </td>",
"       <td class=\"subtitle1\">",
"        City",
"       </td>",
"       <td class=\"subtitle1\">",
"        State",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cypress Surgery Center DBA",
"       </td>",
"       <td>",
"        559-740-4094",
"       </td>",
"       <td>",
"        Visalia",
"       </td>",
"       <td>",
"        CA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encino Outpatient Surgicenter",
"       </td>",
"       <td>",
"        818-986-1037",
"       </td>",
"       <td>",
"        Encino",
"       </td>",
"       <td>",
"        CA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ukiah Valley Medical Center",
"       </td>",
"       <td>",
"        707-463-7345",
"       </td>",
"       <td>",
"        Ukiah",
"       </td>",
"       <td>",
"        CA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Universal Pain Management",
"       </td>",
"       <td>",
"        661-267-6876",
"        <br/>",
"        x166",
"       </td>",
"       <td>",
"        Palmdale",
"       </td>",
"       <td>",
"        CA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interventional Spine And Sports Medicine",
"       </td>",
"       <td>",
"        203-598-7246",
"       </td>",
"       <td>",
"        Middlebury",
"       </td>",
"       <td>",
"        CT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Florida Pain Clinic",
"       </td>",
"       <td>",
"        352-237-5906",
"       </td>",
"       <td>",
"        Ocala",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interventional Rehab Center",
"       </td>",
"       <td>",
"        850-484-8800",
"       </td>",
"       <td>",
"        Pensacola",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marion Pain Management Center",
"       </td>",
"       <td>",
"        352-622-1845",
"       </td>",
"       <td>",
"        Ocala",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        North County Surgicenter",
"       </td>",
"       <td>",
"        561-626-6446",
"       </td>",
"       <td>",
"        Palm Beach Gardens",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orlando Center For Outpatient Surgery",
"       </td>",
"       <td>",
"        407-426-8331",
"       </td>",
"       <td>",
"        Orlando",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain Consultants Of West Florida",
"       </td>",
"       <td>",
"        850-494-0000",
"       </td>",
"       <td>",
"        Pensacola",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery Center Of Ocala",
"       </td>",
"       <td>",
"        352-237-5906",
"       </td>",
"       <td>",
"        Ocala",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical Park Center",
"       </td>",
"       <td>",
"        305-271-9100",
"        <br/>",
"        x226",
"       </td>",
"       <td>",
"        Miami",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forsyth Street Ambulatory Surgery Center",
"       </td>",
"       <td>",
"        478-749-1610",
"       </td>",
"       <td>",
"        Macon",
"       </td>",
"       <td>",
"        GA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain Specialists Of Idaho",
"       </td>",
"       <td>",
"        208-522-7246",
"       </td>",
"       <td>",
"        Idaho Falls",
"       </td>",
"       <td>",
"        ID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walter Knox Memorial Hospital",
"       </td>",
"       <td>",
"        208-365-3561",
"        <br/>",
"        x3342",
"       </td>",
"       <td>",
"        Emmett",
"       </td>",
"       <td>",
"        ID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        APAC Centers For Pain Management",
"       </td>",
"       <td>",
"        708-483-7007",
"       </td>",
"       <td>",
"        Westchester",
"       </td>",
"       <td>",
"        IL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        APAC Centers For Pain Management",
"       </td>",
"       <td>",
"        773-935-2760",
"       </td>",
"       <td>",
"        Chicago",
"       </td>",
"       <td>",
"        IL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thorek Memorial Hospital",
"       </td>",
"       <td>",
"        773-975-6734",
"       </td>",
"       <td>",
"        Chicago",
"       </td>",
"       <td>",
"        IL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambulatory Care Center, LLC",
"       </td>",
"       <td>",
"        812-475-1800",
"       </td>",
"       <td>",
"        Evansville",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fort Wayne Physical Medicine",
"       </td>",
"       <td>",
"        260-436-9337",
"       </td>",
"       <td>",
"        Fort Wayne",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OSMC Outpatient Surgery Center",
"       </td>",
"       <td>",
"        574-266-4173",
"       </td>",
"       <td>",
"        Elkhart",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Bend Clinic",
"       </td>",
"       <td>",
"        574-237-9372",
"       </td>",
"       <td>",
"        South Bend",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Union Hospital",
"       </td>",
"       <td>",
"        812-238-4964",
"       </td>",
"       <td>",
"        Terre Haute",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wellspring",
"       </td>",
"       <td>",
"        812-376-0700",
"       </td>",
"       <td>",
"        Columbus",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baltimore Pain Management",
"       </td>",
"       <td>",
"        410-682-5040",
"       </td>",
"       <td>",
"        Baltimore",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Berlin Interventional Pain Management",
"       </td>",
"       <td>",
"        410-641-3759",
"       </td>",
"       <td>",
"        Berlin",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Box Hill Surgery Center",
"       </td>",
"       <td>",
"        410-877-8141",
"       </td>",
"       <td>",
"        Abingdon",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Greenspring Surgery Center",
"       </td>",
"       <td>",
"        410-653-0077",
"       </td>",
"       <td>",
"        Baltimore",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Harford County ASC, LLC",
"       </td>",
"       <td>",
"        410-538-7000",
"       </td>",
"       <td>",
"        Edgewood",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain Medicine Specialists",
"       </td>",
"       <td>",
"        410-825-6945",
"       </td>",
"       <td>",
"        Towson",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgcenter Of Bel Air",
"       </td>",
"       <td>",
"        410-638-5523",
"       </td>",
"       <td>",
"        Bel Air",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Michigan Neurosurgical Institute",
"       </td>",
"       <td>",
"        810-606-7112",
"       </td>",
"       <td>",
"        Grand Blanc",
"       </td>",
"       <td>",
"        MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Michigan Pain Specialists",
"       </td>",
"       <td>",
"        734-995-7246",
"       </td>",
"       <td>",
"        Brighton",
"       </td>",
"       <td>",
"        MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromuscular &amp; Rehabilitation",
"       </td>",
"       <td>",
"        231-935-0860",
"       </td>",
"       <td>",
"        Traverse City",
"       </td>",
"       <td>",
"        MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Southeast Michigan Surgical Hospital",
"       </td>",
"       <td>",
"        586-427-1000",
"       </td>",
"       <td>",
"        Warren",
"       </td>",
"       <td>",
"        MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maps-Edina Medical Pain Clinic",
"       </td>",
"       <td>",
"        763-537-6000",
"       </td>",
"       <td>",
"        Minneapolis",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maps-Medical Advanced Pain",
"       </td>",
"       <td>",
"        763-537-6000",
"       </td>",
"       <td>",
"        Fridley",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical Advanced Pain Specialists",
"       </td>",
"       <td>",
"        763-537-6000",
"        <br/>",
"        x238",
"       </td>",
"       <td>",
"        Shakopee",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical Advanced Pain Specialists",
"       </td>",
"       <td>",
"        763-537-6000",
"       </td>",
"       <td>",
"        Maple Grove",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minnesota Surgery Center",
"       </td>",
"       <td>",
"        763-767-7139",
"       </td>",
"       <td>",
"        Edina",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minnesota Surgery Center",
"       </td>",
"       <td>",
"        763-537-6000",
"       </td>",
"       <td>",
"        Maple Grove",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High Point Surgery",
"       </td>",
"       <td>",
"        336-878-6048",
"       </td>",
"       <td>",
"        High Point",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        North Carolina Orthopaedic Clinic",
"       </td>",
"       <td>",
"        919-403-5148",
"       </td>",
"       <td>",
"        Durham",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery Center Of Wilson",
"       </td>",
"       <td>",
"        252-237-5649",
"       </td>",
"       <td>",
"        Wilson",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dr. O'Connell's PainCare Center",
"       </td>",
"       <td>",
"        603-335-5070",
"       </td>",
"       <td>",
"        Merrimack",
"       </td>",
"       <td>",
"        NH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dr. O'Connell's PainCare Centers, Inc.",
"       </td>",
"       <td>",
"        603-692-3166",
"       </td>",
"       <td>",
"        Somersworth",
"       </td>",
"       <td>",
"        NH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central Jersey Orthopedics Specialists PC",
"       </td>",
"       <td>",
"        908-561-2122",
"       </td>",
"       <td>",
"        South Plainfield",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edison Surgical Center",
"       </td>",
"       <td>",
"        732-452-0123",
"       </td>",
"       <td>",
"        Edison",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IF Pain Associates/Isaiah Florence",
"       </td>",
"       <td>",
"        201-287-1100",
"       </td>",
"       <td>",
"        Teaneck",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premier Orthopedics Surg. Assoc., LLC",
"       </td>",
"       <td>",
"        856-690-1750",
"       </td>",
"       <td>",
"        Vineland",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comprehensive Pain Management",
"       </td>",
"       <td>",
"        973-796-5216",
"       </td>",
"       <td>",
"        Sparta",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Jersey Health Care",
"       </td>",
"       <td>",
"        856-363-1558",
"       </td>",
"       <td>",
"        Elmer",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Jersey Healthcare",
"       </td>",
"       <td>",
"        856-641-7557",
"       </td>",
"       <td>",
"        Vineland",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sahara Surgery Center",
"       </td>",
"       <td>",
"        702-362-7874",
"       </td>",
"       <td>",
"        Las Vegas",
"       </td>",
"       <td>",
"        NV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Butani, Sunil H. Physician PC",
"       </td>",
"       <td>",
"        516-747-5042",
"       </td>",
"       <td>",
"        Mineola",
"       </td>",
"       <td>",
"        NY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obosa Medical Services",
"       </td>",
"       <td>",
"        914-530-2323",
"       </td>",
"       <td>",
"        Mount Vernon",
"       </td>",
"       <td>",
"        NY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rochester Brain And Spine",
"       </td>",
"       <td>",
"        585-334-5560",
"       </td>",
"       <td>",
"        Rochester",
"       </td>",
"       <td>",
"        NY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BKC Pain Specialists, LLC",
"       </td>",
"       <td>",
"        740-387-7246",
"       </td>",
"       <td>",
"        Marion",
"       </td>",
"       <td>",
"        OH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cincinnati Pain Management",
"       </td>",
"       <td>",
"        513-891-0022",
"       </td>",
"       <td>",
"        Cincinnati",
"       </td>",
"       <td>",
"        OH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marion Pain Clinic",
"       </td>",
"       <td>",
"        740-375-0200",
"       </td>",
"       <td>",
"        Marion",
"       </td>",
"       <td>",
"        OH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ortho-Spine Rehabilitation Center, Inc.",
"       </td>",
"       <td>",
"        614-793-8817",
"       </td>",
"       <td>",
"        Dublin",
"       </td>",
"       <td>",
"        OH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allegheny Pain Management",
"       </td>",
"       <td>",
"        814-940-2000",
"       </td>",
"       <td>",
"        Altoona",
"       </td>",
"       <td>",
"        PA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Hills Pain &amp; Rehab Assoc.",
"       </td>",
"       <td>",
"        412-469-7722",
"       </td>",
"       <td>",
"        Jefferson Hills",
"       </td>",
"       <td>",
"        PA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New England Anesthesiology (NEA)",
"       </td>",
"       <td>",
"        401-490-7530",
"       </td>",
"       <td>",
"        Warwick",
"       </td>",
"       <td>",
"        RI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ocean State Pain Management",
"       </td>",
"       <td>",
"        401-766-7700",
"       </td>",
"       <td>",
"        Woonsocket",
"       </td>",
"       <td>",
"        RI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ocean State Pain Management",
"       </td>",
"       <td>",
"        401-884-6070",
"       </td>",
"       <td>",
"        East Greenwich",
"       </td>",
"       <td>",
"        RI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intervene MD",
"       </td>",
"       <td>",
"        843-216-4844",
"       </td>",
"       <td>",
"        Mount Pleasant",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCA Pain Care Center",
"       </td>",
"       <td>",
"        865-835-5196",
"       </td>",
"       <td>",
"        Oak Ridge",
"       </td>",
"       <td>",
"        TN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specialty Surgery Center",
"       </td>",
"       <td>",
"        931-484-2500",
"        <br/>",
"        x125",
"       </td>",
"       <td>",
"        Crossville",
"       </td>",
"       <td>",
"        TN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        St. Thomas Outpatient Neurosurgical",
"       </td>",
"       <td>",
"        615-341-3425",
"       </td>",
"       <td>",
"        Nashville",
"       </td>",
"       <td>",
"        TN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dallas Back Pain Management",
"       </td>",
"       <td>",
"        214-445-5077",
"       </td>",
"       <td>",
"        Dallas",
"       </td>",
"       <td>",
"        TX",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Harris Methodist Southlake Center",
"       </td>",
"       <td>",
"        817-748-8778",
"       </td>",
"       <td>",
"        Southlake",
"       </td>",
"       <td>",
"        TX",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insight Imaging-Roanoke",
"       </td>",
"       <td>",
"        540-581-0882",
"       </td>",
"       <td>",
"        Roanoke",
"       </td>",
"       <td>",
"        VA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New River Valley Surgery Center",
"       </td>",
"       <td>",
"        540-639-5888",
"       </td>",
"       <td>",
"        Christiansburg",
"       </td>",
"       <td>",
"        VA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PARS Interventional Pain",
"       </td>",
"       <td>",
"        304-865-7277",
"       </td>",
"       <td>",
"        Parkersburg",
"       </td>",
"       <td>",
"        WV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table lists all of the healthcare&nbsp;facilities that got the contaminated steroid medicine. The medicine is called methylprednisolone acetate and was made by New England Compounding Center. The contaminated medicine was used between May 21, 2012 and September 26, 2012.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Healthcare-associated Infections (HAIs): Map of Healthcare Facilities which Received Three Lots of Methylprednisolone Acetate (PF) Recalled from New England Compounding Center on September 26, 2012. Available at:",
"     <a href=\"file://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html\" target=\"_blank\">",
"      file://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html",
"     </a>",
"     (Accessed October 11, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_1_33823=[""].join("\n");
var outline_f33_1_33823=null;
